Original Article
Treatment of Hypertension in Patients 80 Years of Age or Older
N Engl J Med 2008; 358:1887-1898May 1, 2008
- Abstract
Background
Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death.
Methods
We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting–enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke.
Results
The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], −1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, −1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001).
Conclusions
The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811.)
Media in This Article
Figure 1
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial.Figure 2
Mean Blood Pressure, Measured while Patients Were Seated, in the Intention-to-Treat Population, According to Study Group.Article Activity
- Article
Blood-pressure reduction is effective in preventing stroke and other vascular events, including heart failure.1 In the past decade, treatment benefits have appeared to be broadly consistent among a range of subpopulations and among antihypertensive agents.2 However, as highlighted by earlier3 and more recent4 guidelines, evidence that treating patients 80 years of age or older is beneficial is inconclusive. Although the risk of stroke increases continuously with increasing blood pressures above approximately 115/75 mm Hg, the association of blood pressure and stroke attenuates with increasing age.1 Epidemiologic population studies have consistently suggested that blood pressure and the risk of death are inversely related among people 80 years of age or older,5-9 possibly reflecting increased risks of therapy for blood-pressure reduction or reverse causation due to conditions that may be associated with blood-pressure reduction (such as cancer, dementia, myocardial infarction, and heart failure).
A recent retrospective cohort analysis of patients 80 years of age or older with hypertension, of whom 84.5% were receiving antihypertensive medication, reported a shorter survival for those with systolic blood pressure levels below 140 mm Hg, even after adjustment for known predictors of death.10 Randomized controlled trials involving older adults either have excluded those 80 years of age or older11,12 or have recruited too few to show an advantage of treatment.13-16 A meta-analysis of results regarding the treatment of hypertension specifically in this age group suggested that the benefit — a 36% reduction in the risk of stroke — might be offset by possible adverse effects, given a nearly significant increase, by 14%, in the risk of death from any cause (P=0.05).17 These positive results were not robust, since addition of data from just one hypothetical, properly designed trial that showed no treatment effect would render the results not significant.
The results of the pilot study for the Hypertension in the Very Elderly Trial (HYVET)18 were consistent with those from the meta-analysis. Both results suggest that treatment for hypertension was associated with a reduction in stroke but also a possible increase in death from any cause, such that for each stroke prevented, there was one death from a cause other than stroke. In the main HYVET study, we aimed to resolve persistent areas of clinical uncertainty about the relative benefits and risks of antihypertensive treatment in patients 80 years of age or older.
Methods
The detailed protocol for HYVET has been published previously.19 HYVET was a randomized, double-blind, placebo-controlled trial performed in 195 centers in 13 countries in Western and Eastern Europe, China, Australasia, and North Africa. Approval for the trial was obtained from the appropriate authorities and central or local ethics committees, as required. All patients gave written informed consent, except those who were illiterate, for whom an independent witness signed the consent form.
HYVET was funded by grants from the British Heart Foundation and the Institut de Recherches Internationales Servier. The trial was coordinated by staff of the Department of Care of the Elderly, Imperial College London. Imperial College London required all committee members and investigators to sign confidentiality agreements. All data management was performed by the authors who were at Imperial College London. The interim analyses were performed by, and the final analysis verified by, an academic author, independently of Imperial College London. All the authors contributed to the writing of the manuscript and the lead authors vouch for the completeness and accuracy of the results.
Patients had to be 80 years of age or older (confirmed by national documentation) with persistent hypertension (defined as a sustained systolic blood pressure of 160 mm Hg). Exclusion criteria included a contraindication to use of the trial medications, accelerated hypertension, secondary hypertension, hemorrhagic stroke in the previous 6 months, heart failure requiring treatment with antihypertensive medication, a serum creatinine level greater than 150 μmol per liter (1.7 mg per deciliter), a serum potassium level of less than 3.5 mmol per liter or more than 5.5 mmol per liter, gout, a diagnosis of clinical dementia, and a requirement of nursing care.
Patients were instructed to stop all antihypertensive treatment and to take a single placebo tablet daily for at least 2 months and to undergo two blood-pressure measurements during each of two visits, 1 month apart, after having been seated for 5 minutes. On the third visit and thereafter, the standing blood pressure was taken twice, after the patient had been standing for 2 minutes. At the start of the trial, blood pressures were recorded with the use of either a mercury sphygmomanometer or a validated automated device, but by the end of the trial, a validated automated device was used in the majority of centers.
If the mean of the four systolic blood-pressure measurements taken at the second and third visits (two at each visit) was between 160 and 199 mm Hg, patients underwent randomization, provided that all inclusion and exclusion criteria were met. Randomization was stratified according to age (80 to 89 years and 90 years or older) and sex; permuted blocks of 4 and 6 of any 10 patients were used to ensure roughly equal assignment to each of the two groups within large centers. At the start of the trial in 2000, the mean diastolic blood pressure while seated had to be 90 to 109 mm Hg, but in 2003 a protocol amendment relaxed this criterion to be under 110 mm Hg, allowing for the inclusion of patients with isolated systolic hypertension. The criterion of systolic blood pressure while standing remained the same throughout the trial, at 140 mm Hg or more.
After randomization, patients received either indapamide (sustained release, 1.5 mg) or matching placebo alone. At each visit (or at the discretion of the investigator), if needed to reach the target blood pressure, perindopril (2 mg or 4 mg) or matching placebo could be added. The target systolic blood pressure was less than 150 mm Hg, and the target diastolic blood pressure was less than 80 mm Hg. The use of additional antihypertensive agents for more than 3 months resulted in withdrawal of the patient from double-blind follow-up, with an option to enter open follow-up. Patients were also withdrawn from double-blind treatment if they had received the maximum dose of the study drugs yet had a systolic blood pressure while sitting of 220 mm Hg or more or if they had a diastolic blood pressure while sitting of 110 mm Hg or more on at least two consecutive visits that were 2 or more weeks apart.
Data Collection
Baseline characteristics were recorded during the placebo run-in period. After randomization, patients were seen at least every 3 months during the first year and at least every 6 months thereafter. Investigators were permitted to adjust the dose of the trial medication more frequently than at each visit, if desired. At the annual visits, information was collected on current diseases, medication, blood pressure, biochemical levels (sodium, potassium, urea, creatinine, glucose, uric acid), cholesterol levels (total and high-density lipoprotein), and hematologic measures (hemoglobin, hematocrit), and electrocardiography and an assessment of cognitive function with the use of the Mini–Mental State Examination were performed. If the patient was enrolled in an optional add-on study, a quality-of-life questionnaire was also completed. At the 3-month and 6-month visits, only data on current diseases, medication, and blood pressure were collected.
End Points
The primary end point of the trial was any stroke (fatal or nonfatal). This end point did not include transient ischemic attacks. Secondary end points included death from any cause, death from cardiovascular causes, death from cardiac causes, and death from stroke. All events that were possible end points were reviewed by an independent committee, unaware of the group assignment, using predefined definitions from the protocol.19 Events were classified as cardiovascular or noncardiovascular. Death from cardiac causes included fatal myocardial infarction, fatal heart failure, and sudden death. Heart failure was diagnosed if the patient had at least one of four symptoms (paroxysmal nocturnal dyspnea, dyspnea at rest, orthopnea, or symptoms consistent with New York Heart Association class III heart failure20) and at least two of seven signs (rales or crepitations, moderate ankle edema, tachycardia [120 or more beats per minute], a third heart sound, elevated jugular venous pressure, cardiomegaly, or radiologic signs characteristic of heart failure). If the two signs present were rales and ankle edema, a third sign was required.
Data Monitoring
An independent data monitoring committee met twice a year throughout the trial to monitor the quality of the data and also met at prespecified intervals (after every 70 reported stroke events) to perform interim analyses. The interim analyses of the primary end point were monitored according to an O'Brien–Fleming guideline; death from any cause was monitored to detect a possible increased risk in the active-treatment group. On the basis of the committee's recommendations, four centers were closed after the first year of the trial because of concerns that these centers failed to provide complete and accurate data. Specifically, one center was closed because of a failure to identify all the biochemical data in the source documents, one because of a failure to obtain appropriate regulatory approval, one owing to inappropriate drug delivery, and one owing to a failure to use validated equipment for measuring blood pressure.
Statistical Analysis
HYVET was designed to detect a 35% reduction in the rate of any stroke, with a statistical power of 90% at the 1% level of significance and assuming an event rate of 40 per 1000 patient-years. We calculated that 10,500 patient-years of follow-up would be required, with equal numbers of patients assigned to the active-treatment group and the placebo group. The first patient underwent randomization in February 2001. After the first interim analysis in 2005, the data monitoring committee recommended that the trial continue with no change to the protocol. At the second interim analysis, in July 2007, after 140 strokes had been reported (through April 30, 2007; a total of 7399 patient-years of follow-up), the active-treatment group showed evidence of a reduction in the rate of the primary end point of any stroke (relative risk, 0.59; 95% confidence interval [CI], 0.40 to 0.88; P=0.009) and, unexpectedly, for death from any cause (relative risk, 0.76; 95% CI, 0.62 to 0.93; P=0.007). The trial was terminated at that point, for ethical reasons. All final visits were completed by October 12, 2007. Data and events reported before the final visit were included in the final analysis.
The primary analysis was performed according to the intention-to-treat principle. Data from patients were analyzed for the groups to which the patients were assigned, regardless of which study drugs (or which doses) the patients actually received and regardless of other protocol irregularities. Patients from closed centers were included in the intention-to-treat population and contributed person-years and events up to the date of closure of the center, after which no further information was available.
In the intention-to-treat analysis, patient-years were calculated from the date of randomization through the date of death or the last available visit, irrespective of the type of follow-up (double-blind or open). Patients who were withdrawn from double-blind follow-up for reasons other than withdrawal of consent were followed in an open-label fashion, with the same schedule of visits. Events that occurred during the open follow-up period were included in the intention-to-treat analysis. A per-protocol analysis was also performed; it excluded data from any patients who underwent randomization in error, who were stratified incorrectly for either age or sex, or who did not receive the correct, assigned study drugs. For this analysis, patient-years were calculated from the date on which the study drugs were initiated through the time the patient became ineligible to continue with double-blind follow-up, according to the protocol19 (i.e., when the patient had an event that required withdrawal from double-blind treatment).
We compared the means of continuous variables by using the z-test, proportions by using the chi-square test, and incidence rates by using the log-rank test. In the log-rank and Cox analyses of fatal or nonfatal strokes and death from specific causes, death from any cause and death from a cause other than the specific cause, respectively, were regarded as events for which data were censored. Cumulative-incidence curves were estimated by means of the Kaplan–Meier method. P values less than 0.05 were considered to indicate statistical significance. For patients with more than one end point during the follow-up period, the time to the first relevant end point was used in each analysis. Results for death from fatal or nonfatal stroke, death from any cause, and death from cardiovascular causes were adjusted for sex, age, baseline systolic blood pressure measured while the patient was seated, and previous cardiovascular disease. The proportional-hazard assumption was verified by plotting the Schoenfeld residuals. All reported P values are two-sided and were not adjusted for multiple testing. Data management and analyses were performed with the use of Stata software (version 8.1) (StatCorp) and SAS software (version 9.1.3) (SAS Institute).
Results
A total of 4761 patients entered the placebo run-in phase. Of these, 3845 were randomly assigned to one of the two study groups. The reasons for nonrandomization are listed in Figure 1Figure 1
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial.. Patients were recruited from Western Europe (86 patients), Eastern Europe (2144), China (1526), Australasia (19), and Tunisia (70). The two study groups were well balanced at baseline (Table 1Table 1
Baseline Characteristics of the Patients.). The age range at entry was 80 to 105 years, with 73.0% of patients 80 to 84 years of age, 22.4% of patients 85 to 89 years of age, and 4.6% of patients 90 years of age or older (interquartile range, 81.2 to 85.3). More than 90% of patients were known to be hypertensive, of whom approximately one third had not been previously treated. A history of cardiovascular disease was reported in 11.8%, and diabetes was reported in 6.9%.The median duration of follow up was 1.8 years (mean, 2.1; range, 0 to 6.5). The number of patient-years of follow-up was 3964 in the placebo group and 4159 in the active-treatment group. At the end of the trial, vital status was unknown in 17 patients, 1882 patients were still undergoing double-blind follow-up, and 220 patients were undergoing open follow-up.
According to the intention-to-treat analysis, at 2 years, as compared with baseline, the systolic and diastolic blood pressure values obtained while the patient was seated had fallen by a mean (±SD) of 14.5±18.5 mm Hg and 6.8±10.5 mm Hg, respectively, in the placebo group and by 29.5±15.4 mm Hg and 12.9±9.5 mm Hg, respectively, in the active-treatment group. At 2 years, the mean systolic and diastolic blood pressure values obtained while the patient was standing had decreased by 13.6±18.9 mm Hg and 7.0±10.9 mm Hg, respectively, in the placebo group and by 28.3±16.5 mm Hg and 12.4±10.3 mm Hg, respectively, in the active-treatment group. There was a difference of 15.0/6.1 mm Hg in blood pressure, measured while patients were seated, between the two groups at 2 years (Figure 2Figure 2
Mean Blood Pressure, Measured while Patients Were Seated, in the Intention-to-Treat Population, According to Study Group.). Also at 2 years, the target blood pressure was reached in 19.9% of patients in the placebo group and in 48.0% in the active-treatment group (P<0.001).At 2 years, 25.8%, 23.9%, and 49.5% of patients in the active-treatment group were receiving indapamide alone, indapamide and perindopril (2 mg), and indapamide and perindopril (4 mg), respectively; 14.2%, 13.4%, and 71.8% of patients in the placebo group, respectively, were receiving the corresponding placebos. The final main intention-to-treat analysis included an extra 724 patient-years of follow-up, with an additional 13 strokes and 54 deaths. This final analysis confirmed the treatment benefit for the risk of death from any cause and yielded a nearly significant benefit for the risk of fatal or nonfatal stroke.
With regard to the primary end point (fatal or nonfatal stroke), 51 events occurred in the active-treatment group as compared with 69 events in the placebo group, a reduction in the rate of stroke of 30% (95% CI, −1 to 51; P=0.06) (Table 2Table 2
Main Fatal and Nonfatal End Points in the Intention-to-Treat Population. and Figure 3Figure 3
Kaplan–Meier Estimates of the Rate of End Points, According to Study Group.). This is equivalent to 11 strokes (95% CI, 0 to 21) being prevented because 1000 patients were treated for 2 years or 1 stroke being prevented because 94 patients were treated for 2 years. There were a total of 431 deaths during the trial, with an overall rate of death of 53.1 per 1000 patient-years. There was a 21% reduction (95% CI, 4 to 35; P=0.02) in the rate of death from any cause in the active group. The rate of fatal stroke was reduced by 39% (95% CI, 1 to 62; P=0.05). The rate of death from cardiac causes was not significantly reduced in the active-treatment group. The rate of death from cardiovascular causes was reduced by 23% (95% CI, −1 to 40; P=0.06). The rate of fatal or nonfatal heart failure was reduced by 64% (95% CI, 42 to 78; P<0.001), and the rate of any cardiovascular event (death from cardiovascular causes or stroke, myocardial infarction, or heart failure) was reduced by 34% (95% CI, 18 to 47; P<0.001).The benefits of treatment began to be apparent within the first year (Figure 3). When adjusted according to sex, age, baseline systolic blood pressure while seated, and previous cardiovascular disease, the results did not materially change for the end points of fatal or nonfatal stroke, death from any cause, or death from cardiovascular causes.
According to per-protocol analyses, in the active-treatment group as compared with the placebo group, the rate of stroke was reduced by 34% (95% CI, 5 to 54; P=0.03), the rate of any heart failure by 72% (95% CI, 52 to 83; P<0.001), and the rate of death from cardiovascular causes by 27% (95% CI, 3 to 45; P=0.03). In addition, the rate of death from any cause was decreased by 28% (95% CI, 12 to 41; P=0.001) and the rate of death from stroke by 45% (95% CI, 7 to 67; P=0.02).
Among the patients followed for at least 2 years, there were no significant differences between the two groups with regard to changes from baseline in the serum potassium level (−0.02 mmol and 0.03 mmol per liter in the active-treatment group and in the placebo group, respectively; P=0.09), uric acid (11.6 μmol and 3.5 μmol per liter [0.2 and 0.1 mg per deciliter], P=0.07), glucose (0.16 mmol and 0.11 mmol per liter [2.9 and 2.0 mg per deciliter], P=0.56), or creatinine (3.4 μmol and 2.3 μmol per liter [0.04 and 0.03 mg per deciliter], P=0.30). The number of serious adverse events reported was 448 in the placebo group and 358 in the active-treatment group (P=0.001). Only five of these events (three in the placebo group and two in the active-treatment group) were classified by the local investigator as possibly having been due to the trial medication.
Discussion
The results of HYVET indicate that antihypertensive treatment based on indapamide (sustained release, 1.5 mg), with or without 2 to 4 mg of perindopril, significantly reduces the risks of death from stroke and death from any cause in very elderly patients. This finding for stroke is consistent with that seen in the HYVET pilot study18 and the Individual Data Analysis of Antihypertensive Drug Intervention Trials (INDANA) group meta-analysis.17 The reduction in death from any cause is a new and unexpected result.
As compared with clinical trials involving other age groups,11,14-16 the ratio of fatal to nonfatal events was higher in HYVET. Although the number of strokes reported in HYVET (120) was similar to that reported in the Systolic Hypertension in Europe (Syst-Eur)16 trial (128 strokes) and higher than the number reported in the Swedish Trial in Older Patients with Hypertension (STOP–Hypertension, 82 strokes),14 in HYVET the proportion of fatal strokes (57.5%) was higher than that in Syst-Eur (28.9%) or STOP (18.3%). This difference probably reflects the older age of the patients in HYVET and the higher rates of stroke that occur with increasing age.1 Increasing age is a major predictor of death from stroke,21-25 with rates as high as 52%21 in persons 80 years of age or older, consistent with our results. A linear association between blood pressure and stroke reduction has been clearly demonstrated, although it is attenuated by increasing age.25 The reduction in the risk of death from stroke with active treatment was significant in both the intention-to-treat and the per-protocol analyses, as was the reduction in the risk of any stroke in the per-protocol analysis. This reduction is consistent with previous results in younger hypertensive patients and in reviews of data from the very elderly.
An unexpected finding of our trial is the reduction in the risk of death from any cause with active treatment, making HYVET one of the few individual studies of hypertension showing benefits of blood-pressure reduction on mortality.14,26 The results for death from any cause show a significant benefit of treatment, at odds with the results of the INDANA meta-analysis, the largest analysis to date to focus on very elderly patients with hypertension, which included 1670 patients 80 years of age or older recruited for intervention trials.17 The INDANA meta-analysis included trials with treatment regimens based on high doses of diuretics other than indapamide or on beta-blockers. Diuretics have not been shown to increase mortality among younger patients, but the very elderly may be more prone to metabolic disturbances from medications, particularly hypokalemia, which can predispose patients to arrhythmias and possibly sudden death. Beta-blockers appear to be less effective than newer agents in the treatment of hypertension.27 Given the known changes in serum potassium level that can occur with a thiazide-like antihypertensive agent or angiotensin-converting–enzyme (ACE) inhibitor on its own, in combination, they are likely to have a neutral effect. This was evidenced by the similar serum potassium levels in the two groups, with 73.4% of patients in the active-treatment group receiving both indapamide and perindopril at 2 years. Indapamide (sustained release) has also been shown to have a neutral effect on blood glucose and lipids,28 and the combination of indapamide and perindopril has also been shown to confer a benefit with regard to stroke.29
As in most trials, the patients in HYVET were generally healthier than those in the general population, as evidenced by the low overall rates of stroke and death from any cause and the low prevalence of previous cardiovascular disease at baseline. It is possible that the numbers of patients needed to be treated is an overestimate, given the low rate of stroke, though a number needed to treat of 94 is acceptable in the context of prevention. A number needed to treat of 40 to prevent one death during a 2-year period is more impressive, supporting the effectiveness of the intervention used. However, it would be premature to extrapolate the results from HYVET to patients in this age group who are more frail.
The large reduction in the risk of heart failure in HYVET appears to be important. Heart failure is common in people older than 70 years of age, and hypertension is a major risk factor for heart failure.30 The combination of a diuretic and an ACE inhibitor is likely to confer a benefit. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT; ClinicalTrials.gov number, NCT00000542), the lowest rates of hospitalization and fatal heart failure were found for the groups receiving a diuretic or ACE inhibitor, with a greater (albeit not significantly greater) reduction in the diuretic group.31
A challenge and possible limitation in performing our study of the very elderly was the collection of adequate information to validate the end-point data, especially for patients who died at home without receiving any direct medical intervention. The end-point committee required evidence to support a diagnosis of a stroke, and this evidence was not always available. Rapid and unexpected deaths were designated as deaths from cardiovascular causes by the committee. In the very elderly, it is difficult to establish the exact cause of death, since patients are often not monitored during the last hours of life and autopsies are rarely performed. Given these difficulties, the reduction of the risk of death from any cause in the active-treatment group clearly indicates the overall advantage of active treatment in HYVET.
In HYVET, we evaluated the benefit of treating patients who had a sustained systolic blood pressure of 160 mm Hg or higher. The fall in blood pressure in the active-treatment group was consistent with results for indapamide-based strategies in other studies.32,33 The results support a target blood pressure of 150/80 mm Hg in patients receiving treatment, since that target was reached in nearly 50% of such patients in HYVET after 2 years. Whether further reduction is beneficial still needs to be established.
Elevated blood pressure is common in persons 80 years of age or older,34 a group constituting the fastest-growing segment of the general population.35 HYVET provides unique evidence that hypertension treatment based on indapamide (sustained release), with or without perindopril, in the very elderly, aimed to achieve a target blood pressure of 150/80 mm Hg, is beneficial and is associated with reduced risks of death from stroke, death from any cause, and heart failure.
Supported by grants from the British Heart Foundation and the Institut de Recherches Internationales Servier.
Drs. Beckett and Peters and Mr. Banya report receiving grant support from the Institut de Recherches Internationales Servier; Dr. Staessen, consulting fees from Pfizer, Tanabe, Daiichi-Sankyo, and Sigma-Tau and speakers' fees from Pfizer, Tanabe, and Bayer; Dr. Anderson, consulting fees from Boehringer Ingelheim and Servier and speakers' fees from Boehringer Ingelheim, Servier, AstraZeneca, and Sanofi-Aventis; Dr. Forette, consulting fees from Wyeth Elan, Sanofi-Aventis and Bristol-Myers Squibb and speakers' fees from Servier, AstraZeneca, and Sanofi-Aventis; Dr. Rajkumar, speakers' fees from Schering-Plough, Merck Sharp & Dohme, and Menarini; and Dr. Bulpitt, consulting fees from Imperial College Consulting, a consultancy funded by a grant from the Institut de Recherches Internationales Servier. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0801369) was published at www.nejm.org on March 31, 2008.
Source Information
From Imperial College London (N.S.B., R.P., R.L.A., W.B., C.J.B.) and the London School of Hygiene and Tropical Medicine (A.E.F.) — both in London; the University of Leuven, Leuven, Belgium (J.A.S., L.T.); the Beijing Hypertension League Institute, Beijing (L.L.); Spitalul Judetean Cluj, Clinica Medicală 2, Cluj, Romania (D.D.); the National Transport Multi-Profile Hospital, Sofia, Bulgaria (V.S.); the University of Oulu, Oulu, Finland (R.L.A.); the State Scientific Research Institute of Internal Medicine, Novosibirsk, Russia (Y.N.); the George Institute for International Health, Sydney (C.A.); L'Etablissement Public de Santé Charles Nicolle, Service de Cardiologie, Tunis, Tunisia (A.B.); Hôpital Broca, University Paris V, Paris (F.F.); and the Brighton and Sussex Medical School, Brighton, United Kingdom (C.R.).
Address reprint requests to Dr. Beckett at Care of the Elderly, Division of Medicine, Imperial College London, Du Cane Rd., London W12 ONN, United Kingdom.
The committee members and investigators for the Hypertension in the Very Elderly Trial (HYVET) are listed in the Appendix.
Appendix
The committee members and investigators for HYVET were as follows: Coordinating Center: C.J. Bulpitt (lead investigator), A.E. Fletcher (coinvestigator), N.S. Beckett (trial coordinator), R. Peters (deputy trial coordinator), HYVET coordinating team at Imperial College London (1999 to 2008); Steering Committee: T. McCormack, J. Potter, B.G. Extremera, P. Sever, F. Forette, D. Dumitrascu, C. Swift, J. Tuomilehto, J. Coope (retired in 2001), C. Nachev (deceased); Data Monitoring Committee: J. Staessen, L. Thijs, R. Clarke, K. Narkiewicz; End Points Committee: C. Davidson (retired in 2003), J. Duggan, G. Leonetti, N. Gainsborough, M.C. De Vernejoul, J. Wang, V. Stoyanovsky; Dementia Validation Committee: J. Tuomilehto, R. Clarke, A. Waldman, I. Walton, C. Ritchie; Ethics Committee: R. Fagard, J. Grimley Evans, B. Williams; Investigators: Australia — R. Warne and I. Puddey (national coordinators), M. Woodward, R. Penhall, C. Inderjeeth, S. Roger, R. Scholes, C. Johnson; Belgium — H. Celis (national coordinator), G. Adriaens, W. Onsea, K. Cornelli, D. Vantroyen, P. Cleen, P. de Voogt; Bulgaria — C. Nachev (deceased) (national coordinator from 1998 to 2005), V. Stoyanovsky (national coordinator after 2005), P. Solakov, R. Prokopova, E. Mantova, D. Smilkova, S. Mantov, K. Yankulova, R. Kermova, D. Popov, V. Sirakova, V. Gergova, D. Kamenova, F. Grigorov, T. Vassileva, R. Alahverdian, M. Tzekova; China — L. Liu (national coordinator), H. Ge, S. Wang, J. Wang, W. Zhang, S. Jin, L. Ge, Y.F. Lu, S. Ma, L. Shen, J. Guo, Z. Lv (deceased), R. Huang, X. Li, B. Guo, T. Zhang, L. Zhang, J. Feng, Z. He, J. Wang, L. Deng, L. Liu, Q. Yuan, F. Zhang, H. Li, D. Wang, K. Yang, M. Sun, H. Liu, X. Yan, F. Ren, J. Tang; Finland — R. Antikainen (national coordinator), T. Strandberg, T. Konttila, A. Hynninen, M. Jääskivi, J. Airas, T. Jääskeläinen, J. Tuomilehto, H. Litmanen; France — F. Forette (national coordinator), J. Doucet, J. Belmin, A. Benetos, G. Berrut, T. Boge, M. Bonnefoy, A. Carre, N. Charasz, J. Covillard, T. Dantoine, M. Escande, Y. Frances, R. Joire, C. Jeandel, S. Legrain, A. Lion, M. Maillet-Vioud, J.P. Escaillas, S. Meaume, P. Pfitzenmeyer, F. Puisieux, E. Quercy, O. Rodat, J. Soubeyrand, B. de Wazieres, H. Hindennach, L. Lugassy, J. Rossi, M. Martel, J.-M. Paladel, C. Ravier, A. Visconti, J.P. Gallet, D. Zygouritsas, D. Charles, F. Flamand, G. Grandmottet, M. Grandmottetegermann, C. Gevrey, P.L. Mesnier, G. Robert, C. Besset-Prat, A. Brousse, P. Lafont, J. Morelli, P. Vernede, A. Volkmann, X. Bodin, B. Destrube, R. Eoche, A. Boye, F. Seropian, P. Gernigon, D. Meker, J. Thomere, Y. Thual, F. Volny, E. Grassart, M. Herent, D. Lejay, J.-P. Lopez, B. Mannessier, G. Pruvost, J.-C. Urbina; Ireland — J. Duggan (national coordinator); New Zealand — C. Anderson (national coordinator), S. Lillis, J. Gommans; Poland — T. Grodzicki (national coordinator), Z. Chodorowski, Z. Gaciong; Romania — D. Dumitrascu (national coordinator), M. Comsa, V. Sandru, G. Prada, M. Dunca-Moisin, D. Jianu, D. Jinga-Lazar, V. Enachescu, C. Zaharia; Russia — Y. Nikitin (national coordinator), A. Kirichenko, L. Olbinskaya, A. Martynov, V. Zadionchenko, V. Moiseev, G. Storohzakov, S. Nedogoda, R.S. Karpov, O. Barbarash, G. Efremushkin, V. Kostenko, M. Boyarkin, S. Churina, T. Tyurina, M. Ballyuzek, L. Ermoshkina, A. Timofeev, S. Yakusheva, N. Shilkina, V. Barbarich; Tunisia — A. Belhani (national coordinator), E. Boughzela, S. Soraya, B. Youssef-Zouari, A.B. Khalfallah, M.H. Houman, A.K. Abida; United Kingdom — C. Rajkumar (national coordinator), M. Wilkins, N.D. Pandita-Gunawardena, J. Potter, E. Ekpo, M. Price, N. de Kare-Silver, A. Starczewski, S. Chandran, N. Nasar, M. Datta-Chaudhuri, T. McCormack, N. Majmudar, A. Gordon, L. Brawn, T. Solanki.
- References
References
1
Lawes CM ,Bennett DA ,Feigin VL ,Rodgers A . Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:1024-1024
CrossRef | Web of Science | Medline2
Neal B ,MacMahon S ,Chapman N . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-1964
CrossRef | Web of Science | Medline3
World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183
Web of Science | Medline4
Mancia G ,De Backer G ,Dominiczak A , et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187[Erratum, J Hypertens 2007;25:1749.]
CrossRef | Web of Science | Medline5
Mattila K ,Haavisto M ,Rajala S ,Heikinheimo R . Blood pressure and five year survival in the very old. Br Med J (Clin Res Ed) 1988;296:887-889
CrossRef | Web of Science | Medline6
Langer RD ,Criqui MH ,Barrett-Connor EL ,Klauber MR ,Ganiats TG . Blood pressure change and survival after age 75. Hypertension 1993;22:551-559
Web of Science | Medline7
Rastas S ,Pirttila T ,Viramo P , et al. Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc 2006;54:912-918
CrossRef | Web of Science | Medline8
van Bemmel T ,Woittiez K ,Blauw GJ , et al. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. J Am Soc Nephrol 2006;17:2561-2566
CrossRef | Web of Science | Medline9
Satish S ,Freeman DH Jr ,Ray L ,Goodwin JS . The relationship between blood pressure and mortality in the oldest old. J Am Geriatr Soc 2001;49:367-374
CrossRef | Web of Science | Medline10
Oates DJ ,Berlowitz DR ,Glickman ME ,Silliman RA ,Borzecki AM . Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007;55:383-388
CrossRef | Web of Science | Medline11
Coope J ,Warrender TS . Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986;293:1145-1151
CrossRef | Web of Science | Medline12
Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-412
CrossRef | Web of Science13
Amery A ,Birkenhager W ,Brixko P , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-1354
CrossRef | Web of Science | Medline14
Dahlof B ,Lindholm LH ,Hansson L ,Schersten B ,Ekbom T ,Wester PO . Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285
CrossRef | Web of Science | Medline15
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264
CrossRef | Web of Science16
Staessen JA ,Fagard R ,Thijs L , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764
CrossRef | Web of Science | Medline17
Gueyffier F ,Bulpitt C ,Boissel JP , et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999;353:793-796
CrossRef | Web of Science | Medline18
Bulpitt CJ ,Beckett NS ,Cooke J , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003;21:2409-2417
CrossRef | Web of Science | Medline19
Bulpitt C ,Fletcher A ,Beckett N , et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001;18:151-164
CrossRef | Web of Science | Medline20
The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown, 1994.
21
Hollander M ,Koudstaal PJ ,Bots ML ,Grobbee DE ,Hofman A ,Breteler MM . Incidence, risk, and case fatality of first ever stroke in the elderly population: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2003;74:317-321
CrossRef | Web of Science | Medline22
de Jong G ,van RL ,Kessels F ,Lodder J . Stroke subtype and mortality: a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262-268
CrossRef | Web of Science | Medline23
Kammersgaard LP ,Jorgensen HS ,Reith J ,Nakayama H ,Pedersen PM ,Olsen TS . Short- and long-term prognosis for very old stroke patients: the Copenhagen Stroke Study. Age Ageing 2004;33:149-154
CrossRef | Web of Science | Medline24
Zuliani G ,Cherubini A ,Ranzini M ,Ruggiero C ,Atti AR ,Fellin R . Risk factors for short-term mortality in older subjects with acute ischemic stroke. Gerontology 2006;52:231-236
CrossRef | Web of Science | Medline25
Lewington S ,Clarke R ,Qizilbash N ,Peto R ,Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913
CrossRef | Web of Science | Medline26
Five-year findings of the Hypertension Detection and Follow-up ProgramI. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1997;277:157-166
CrossRef | Web of Science27
Dahlof B ,Sever PS ,Poulter NR , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
CrossRef | Web of Science | Medline28
Ambrosioni E ,Safar M ,Degaute JP , et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998;16:1677-1684
CrossRef | Web of Science | Medline29
PROGRESS Collaborative Group
CrossRef | Web of Science | Medline30
Stewart S ,MacIntyre K ,Capewell S ,McMurray JJ . Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003;89:49-53
CrossRef | Web of Science | Medline31
Davis BR ,Piller LB ,Cutler JA , et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006;113:2201-2210
CrossRef | Web of Science | Medline32
Puig JG ,Marre M ,Kokot F , et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens 2007;20:90-97
CrossRef | Web of Science | Medline33
Emeriau JP ,Knauf H ,Pujadas JO , et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001;19:343-350
CrossRef | Web of Science | Medline34
Callow AD . Cardiovascular disease 2005 -- the global picture. Vascul Pharmacol 2006;45:302-307
CrossRef | Web of Science | Medline35
U.S. Census Bureau. International Data Base (IDB). (Accessed April 7, 2008, at http://www.census.gov/ipc/www/idb/.)
- Citing Articles (355)
Citing Articles
1
C. Escobar, V. Barrios, L. Manzano. (2012) Relevancia de la enfermedad arterial periférica en sujetos de edad avanzada. Hipertensión y Riesgo Vascular
CrossRef2
Toshio Ogihara, Masunori Matsuzaki, Seiji Umemoto, Hiromi Rakugi, Hiroaki Matsuoka, Kazuyuki Shimada, Jitsuo Higaki, Sadayoshi Ito, Akira Kamiya, Hiromichi Suzuki, Yasuo Ohashi, Kazuaki Shimamoto, Takao Saruta. (2012) Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertension Research
CrossRef3
M Thoenes, D Spirk, M Böhm, F Mahfoud, L Thevathasan, P Bramlage. (2012) Treatment of hypertension in the elderly: data from an international cohort of hypertensives treated by cardiologists. Journal of Human Hypertension
CrossRef4
William C. Cushman, Barry R. Davis, Sara L. Pressel, Jeffrey A. Cutler, Paula T. Einhorn, Charles E. Ford, Suzanne Oparil, Jeffrey L. Probstfield, Paul K. Whelton, Jackson T. Wright, Michael H. Alderman, Jan N. Basile, Henry R. Black, Richard H. Grimm, Bruce P. Hamilton, L. Julian Haywood, Stephen T. Ong, Linda B. Piller, Lara M. Simpson, Carol Stanford, Robert J. Weiss, . (2012) Mortality and Morbidity During and After the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. The Journal of Clinical Hypertension 14:1, 20-31
CrossRef5
Eric Judd, David A. Calhoun. (2012) Hypertension and orthostatic hypotension in older patients. Journal of Hypertension 30:1, 38-39
CrossRef6
Daniel Suissa, Paul Brassard, Brielan Smiechowski, Samy Suissa. (2012) Number needed to treat is incorrect without proper time-related considerations. Journal of Clinical Epidemiology 65:1, 42-46
CrossRef7
Alberto Mazza, Emilio Ramazzina, Stefano Cuppini, Michela Armigliato, Laura Schiavon, Ciro Rossetti, Marco Marzolo, Giancarlo Santoro, Roberta Ravenni, Marco Zuin, Sara Zorzan, Domenico Rubello, Edoardo Casiglia. (2012) Antihypertensive Treatment in the Elderly and Very Elderly: Always “the Lower, the Better?”. International Journal of Hypertension 2012, 1-4
CrossRef8
K. E. Kramoh, E. Aké-Traboulsi, C. Konin, Y. N'goran, I. Coulibaly, A. Adoubi, J. Koffi, J. B. Anzouan-Kacou, M. Guikahue. (2012) Management of Hypertension in the Elderly Patient at Abidjan Cardiology Institute (Ivory Coast). International Journal of Hypertension 2012, 1-6
CrossRef9
Stanley S. Franklin. (2012) What Can We Learn From the American Heart Association and American College of Cardiology Expert Consensus Document on Geriatric Hypertension?. Clinical Cardiology 35:1, 1-2
CrossRef10
Carlos Brotons, Núria Soriano, Irene Moral, Fernando Rodríguez-Artalejo, José Ramón Banegas, José María Martín-Moreno. (2012) Intervenciones preventivas en el ámbito de la atención primaria. El ejemplo del PAPPS. Informe SESPAS 2012. Gaceta Sanitaria
CrossRef11
Anna Oliveras, Daniel Batlle. 2012. Isolated systolic hypertension. , 476-480.
CrossRef12
Daniel J Ryan, Conal J Cunningham, Chie Wei Fan. (2011) Non-pharmacological management of orthostatic hypotension in the older patient. Reviews in Clinical Gerontology1-11
CrossRef13
J. W. Blom, W. Ruijter, J. C. M. Witteman, W. J. J. Assendelft, M. M. B. Breteler, A. Hofman, J. Gussekloo. (2011) Changing prediction of mortality by systolic blood pressure with increasing age: the Rotterdam study. AGE
CrossRef14
Niels Engberding, Nanette K Wenger. (2011) Management of hypertension in women. Hypertension Research
CrossRef15
Norman M. Kaplan. (2011) Can Treating the Diastolic Blood Pressure Below a Certain Value Increase Cardiovascular Risk?. Current Cardiology Reports 13:6, 517-519
CrossRef16
J. A. García-Donaire, J. Segura, C. Cerezo, L. M. Ruilope. (2011) A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Pressure 20:6, 322-334
CrossRef17
Marika Salminen, Ismo Räihä, Jarna Heinonen, Sirkka-Liisa Kivelä. (2011) Morbidity in aged Finns: A systematic review. Archives of Gerontology and Geriatrics
CrossRef18
Susan R. Kirsh, David C. Aron. (2011) Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging 28:12, 945-960
CrossRef19
J.-J. Perrenoud. (2011) Ethical considerations in geriatric cardiology. European Geriatric Medicine 2:6, 363-370
CrossRef20
I. Lazareth, P. Priollet. (2011) Actualités du 45e Congrès du Collège Français de Pathologie Vasculaire (CFPV) Paris, 16–18 mars 2011. Journal des Maladies Vasculaires 36, S1-S9
CrossRef21
Gary E. Sander, Thomas D. Giles. (2011) What Is the Blood Pressure Goal for the Elder Patient 75 Years of Age or Older?. Current Cardiology Reports 13:6, 485-491
CrossRef22
R. Düsing. (2011) Therapie der Hypertonie mit Diuretika. Der Internist 52:12, 1484-1491
CrossRef23
Linping Wu, Wasaporn Chanput, Rotimi Aluko, Jianping Wu, Yasumi Horimoto, Shuryo Nakai. 2011. Computer-Aided Optimization of Peptide Sequences and Integrated Delivery of Selected Peptides to Targets. , 313-334.
CrossRef24
Frank Ruschitzka. (2011) Evidence for improvement in survival with antihypertensive combination treatment. Journal of Hypertension 29, S9-S14
CrossRef25
Nobuyuki Shiba, Hiroaki Shimokawa. (2011) Prospective care of heart failure in Japan: lessons from CHART studies. The EPMA Journal 2:4, 425-438
CrossRef26
Tatsuo Hosoya, Satoru Kuriyama, Iwao Ohno, Tetsuya Kawamura, Makoto Ogura, Masato Ikeda, Masahiro Ishikawa, Fumihiro Hayashi, Tatsuya Kanai, Haruo Tomonari, Michimasa Soejima, Kiyoaki Akaba, Goro Tokudome. (2011) Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. Clinical and Experimental Nephrology
CrossRef27
I. Maeve Rea, Susan E. McNerlan, Denis H. Alexander, Michelle E. Armstrong. (2011) Blood pressure and TNF-α act synergistically to increase leucocyte CD11b adhesion molecule expression in the BELFAST study: implications for better blood pressure control in ageing. AGE
CrossRef28
Yuhei Kawano, Toshio Ogihara, Takao Saruta, Yoshio Goto, Masao Ishii. (2011) Association of Blood Pressure Control and Metabolic Syndrome With Cardiovascular Risk in Elderly Japanese: JATOS Study. American Journal of Hypertension 24:11, 1250-1256
CrossRef29
J. Hoyer, H. Haller. (2011) Was gibt es Neues in der Hypertonie?. Der Nephrologe 6:6, 510-517
CrossRef30
R. Whiting, Q. Shen, W. T. Hung, D. Cordato, D. K. Y. Chan. (2011) Predictors for 5-year survival in a prospective cohort of elderly stroke patients. Acta Neurologica Scandinavica 124:5, 309-316
CrossRef31
John K. Hix, Stephen Silver, Richard H. Sterns. (2011) Diuretic-Associated Hyponatremia. Seminars in Nephrology 31:6, 553-566
CrossRef32
B. L. Ng, M. Anpalahan. (2011) Management of chronic kidney disease in the elderly. Internal Medicine Journal 41:11, 761-768
CrossRef33
Toshiharu Ninomiya. (2011) Is Metabolic Syndrome a Risk Factor for Cardiovascular Disease in Late Elderly?. American Journal of Hypertension 24:11, 1193-1193
CrossRef34
Jennifer G. Robinson, Catherine Rahilly-Tierney, Elizabeth Lawler, J. Michael Gaziano. (2011) Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. Journal of Clinical Lipidology
CrossRef35
M. Coutaz, K. Iglesias, J. Morisod. (2011) Is there a risk of orthostatic hypotension associated with antihypertensive therapy in geriatric inpatients?. European Geriatric Medicine
CrossRef36
U.M. Vischer. (2011) The treatment of hypertension in very old persons: Benefits and limitations. European Geriatric Medicine
CrossRef37
Luis M. Ruilope. (2011) Current challenges in the clinical management of hypertension. Nature Reviews Cardiology
CrossRef38
Wilbert S. Aronow, Maciej Banach. (2011) Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Pressure1-3
CrossRef39
P. S. Sever, F. H. Messerli. (2011) Hypertension management 2011: optimal combination therapy. European Heart Journal 32:20, 2499-2506
CrossRef40
Joseph L. Izzo Jr, Howard S. Weintraub, Daniel A. Duprez, Das Purkayastha, Dion Zappe, Rita Samuel, William C. Cushman. (2011) Treating Systolic Hypertension in the Very Elderly With Valsartan-Hydrochlorothiazide vs Either Monotherapy: ValVET Primary Results. The Journal of Clinical Hypertension 13:10, 722-730
CrossRef41
Jörg Slany. (2011) Blutdruck Zielwerte auf dem Prüfstand. Wiener klinische Wochenschrift 123:19-20, 571-584
CrossRef42
Debbie L. Cohen, Raymond R. Townsend. (2011) Update on Pathophysiology and Treatment of Hypertension in the Elderly. Current Hypertension Reports 13:5, 330-337
CrossRef43
Martin G. Myers. (2011) Implications of Ambulatory Blood Pressure Monitoring Substudies on the Interpretation of Clinical Trials in Hypertension: Should the Threshold for Drug Therapy Be Lower in Older Patients?. The Journal of Clinical Hypertension 13:10, 703-705
CrossRef44
Alicia Gutiérrez-Misis, Maria T. Sánchez-Santos, Jose R. Banegas, Maria V. Zunzunegui, Maria V. Castell, Angel Otero. (2011) Prevalence and incidence of hypertension in a population cohort of people aged 65 years or older in Spain. Journal of Hypertension 29:10, 1863-1870
CrossRef45
Franz H. Messerli, Sripal Bangalore. (2011) Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies. The American Journal of Medicine 124:10, 896-899
CrossRef46
Jan Szewieczek, J. Dulawa, J. Gminski, A. Kurek, K. Legierska, T. Francuz, I. Włodarczyk-Sporek, M. Janusz-Jenczen, B. Hornik. (2011) Better cognitive and physical performance is associated with higher blood pressure in centenarians. The journal of nutrition, health & aging 15:8, 618-622
CrossRef47
Massimo Volpe, Giuliano Tocci. (2011) Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. American Journal of Hypertension 24:10, 1060-1068
CrossRef48
Zachary A. Marcum, Linda F. Fried. (2011) Aging and antihypertensive medication-related complications in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension 20:5, 449-456
CrossRef49
Daniel Pella. (2011) Efficacy and Safety of Treatment of Hypertensive Patients with Fixed Combination Perindopril/Indapamide Up to 10/2.5 mg. High Blood Pressure & Cardiovascular Prevention 18:3, 107-113
CrossRef50
Stephanie Alison Ward, Seema Parikh, Barbara Workman. (2011) Health perspectives: International epidemiology of ageing. Best Practice & Research Clinical Anaesthesiology 25:3, 305-317
CrossRef51
L. Reig-Puig, I. Antón-Rodrigo, P. Sánchez-Ferrín. (2011) Relación entre hipertensión arterial y la demencia. Hipertensión y Riesgo Vascular 28:5-6, 182-195
CrossRef52
Krzysztof Narkiewicz. (2011) Angiotensin II receptor blocker combinations: From guidelines to clinical practice. Blood Pressure1-9
CrossRef53
Devasmita Choudhury, Moshe Levi. (2011) Kidney aging—inevitable or preventable?. Nature Reviews Nephrology 7:12, 706-717
CrossRef54
M Qvarnström, B Wettermark, C Ljungman, R Zarrinkoub, J Hasselström, K Manhem, A Sundström, T Kahan. (2011) Antihypertensive treatment and control in a large primary care population of 21 167 patients. Journal of Human Hypertension 25:8, 484-491
CrossRef55
Ikechi G Okpechi, Brian L Rayner. (2011) Impact of recent landmark clinical trials on hypertension treatment. Clinical Investigation 1:8, 1141-1154
CrossRef56
Miles D. Witham. (2011) Drug Trials and Older People. Drugs & Aging 28:8, 679-680
CrossRef57
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef58
M. Endres, M. Grond, W. Hacke, M. Ebinger, P.D. Schellinger, M. Dichgans. (2011) Grenzentscheidungen in der Schlaganfalltherapie. Der Nervenarzt 82:8, 957-972
CrossRef59
H.J. Audebert. (2011) Schlaganfallbehandlung 2011. Notfall + Rettungsmedizin 14:5, 413-424
CrossRef60
Ramón Cristófol Allué, Francesc Manzanares Brotons. (2011) Efficacy and safety of manidipine in patients with hypertension aged 70 years or older. Aging Health 7:4, 521-528
CrossRef61
Ikuo Saito, Hiromichi Suzuki, Shigeru Kageyama, Takao Saruta. (2011) Treatment of Hypertension in Patients 85 Years of Age or Older: A J-BRAVE Substudy. Clinical and Experimental Hypertension 33:5, 275-280
CrossRef62
Ehud Grossman, Franz H. Messerli. (2011) Management of Blood Pressure in Patients With Diabetes. American Journal of Hypertension 24:8, 863-875
CrossRef63
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef64
Laura L. Hayman, Liz Helden, Deborah A. Chyun, Lynne T. Braun. (2011) A life course approach to cardiovascular disease prevention. European Journal of Cardiovascular Nursing 10, S20-S31
CrossRef65
Lorenzo Ghiadoni. (2011) Perindopril for the treatment of hypertension. Expert Opinion on Pharmacotherapy 12:10, 1633-1642
CrossRef66
Leanne Groban, Sarah Lindsey, Hao Wang, Marina S. Lin, Kimberly A. Kassik, Frederico S. M. Machado, Christy S. Carter. (2011) Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 × Brown Norway male rats. AGE
CrossRef67
Brent M Egan, Marilyn A Laken. (2011) Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets?. Current Opinion in Cardiology 26:4, 300-307
CrossRef68
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef69
Peter W de Leeuw. (2011) Combination perindopril/indapamide for the treatment of hypertension: A review. Expert Opinion on Pharmacotherapy1-7
CrossRef70
Y. Zhang, X. Zhang, L. Liu, A. Zanchetti, . (2011) Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. European Heart Journal 32:12, 1500-1508
CrossRef71
Joel Neutel, Dean J. Kereiakes, Kathy A. Stoakes, Jen-Fue Maa, Ali Shojaee, William F. Waverczak. (2011) Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil/Hydrochlorothiazide-Based Treatment Algorithm in Elderly Patients (Age ≥65 Years) Stratified by Age, Sex and Race. Drugs & Aging 28:6, 477-490
CrossRef72
R E Schmieder, M Böhm. (2011) Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Journal of Human Hypertension 25:6, 354-363
CrossRef73
A. Bahrmann, P. Bahrmann, A. Zeyfang, P. Oster. (2011) Diabetes und kardiovaskuläre Erkrankungen im Alter. Zeitschrift für Gerontologie und Geriatrie 44:3, 172-176
CrossRef74
Teresa Badia Farré, Francesc Formiga Perez, Jesús Almeda Ortega, Assumpta Ferrer Feliu, Sonia Rojas-Farreras. (2011) Relación entre presión arterial y mortalidad a los 4 años de seguimiento en una cohorte de individuos mayores de 80 años. Medicina Clínica 137:3, 97-103
CrossRef75
Wilbert S. Aronow. (2011) Office Management of Hypertension in Older Persons. The American Journal of Medicine 124:6, 498-500
CrossRef76
Ahmed Alhusban, Susan C. Fagan. (2011) Secondary Prevention of Stroke in the Elderly: A Review of the Evidence. The American Journal of Geriatric Pharmacotherapy 9:3, 143-152
CrossRef77
Manuel Gorostidi, Alejandro de la Sierra. (2011) Tratamiento de la hipertensión arterial en el paciente muy anciano. Medicina Clínica 137:3, 111-112
CrossRef78
Avraham Weiss, Yichayaou Beloosesky, Riad Majadla, Ehud Grossman. (2011) Blood pressure monitoring in the assessment of old patients with acute stroke. International Journal of Stroke 6:3, 182-186
CrossRef79
S.S. Franklin. (2011) The J-curve of cardiovascular disease risk and how it relates to isolated systolic hypertension. Hipertensión y Riesgo Vascular 28:3, 99-101
CrossRef80
Adam Darowski, Robert Whiting. (2011) Cardiovascular medication and falls. Reviews in Clinical Gerontology 21:02, 170-179
CrossRef81
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef82
Luis Castilla Guerra, María Carmona González, Jesús Álvarez Suero, María del Carmen Fernández Moreno. (2011) ¿Cuándo y hasta cuánto debemos bajar la presión arterial sistólica en los ancianos? El debate continúa. Revista Española de Geriatría y Gerontología 46:3, 172
CrossRef83
Adie Viljoen, Alan J. Sinclair. (2011) Diabetes and Insulin Resistance in Older People. Medical Clinics of North America 95:3, 615-629
CrossRef84
Milta O. Little. (2011) Hypertension: How Does Management Change with Aging?. Medical Clinics of North America 95:3, 525-537
CrossRef85
Carole Pornet, Isabelle Bourdel-Marchasson, Pierre Lecomte, Eveline Eschwège, Isabelle Romon, Sandrine Fosse, Frank Assogba, Candice Roudier, Anne Fagot-Campagna. (2011) Trends in the quality of care for elderly people with type 2 diabetes: The need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys). Diabetes & Metabolism 37:2, 152-161
CrossRef86
Steen Neldam, Robert M Guthrie. (2011) Telmisartan/hydrochlorothiazide single-pill combination in the treatment of hypertension in elderly patients. Aging Health 7:2, 249-264
CrossRef87
Jean-Michel Mallion, Stefano Omboni, John Barton, Walter Van Mieghem, Krzysztof Narkiewicz, Peter-Klaus Panzer, Juan García Puig, Christodoulos Stefanadis, Robert Zweiker. (2011) Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Blood Pressure 20:S1, 3-11
CrossRef88
Krishna K. Gaddam, Hector O. Ventura, Carl J. Lavie. (2011) Metabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment. Current Hypertension Reports 13:2, 142-148
CrossRef89
Firas J. Al Badarin, Mohammad A. Abuannadi, Carl J. Lavie, James H. O'Keefe. (2011) Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic Hypertension. The American Journal of Cardiology 107:8, 1178-1184
CrossRef90
Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz, Maciej Banach. (2011) The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Current Cardiovascular Risk Reports 5:2, 174-179
CrossRef91
Mukul Sharma, Antoine M. Hakim. (2011) The management of hypertension for primary stroke prevention: a proposed approach. International Journal of Stroke 6:2, 144-149
CrossRef92
C J Bulpitt, N S Beckett, R Peters, G Leonetti, V Gergova, R Fagard, L A Burch, W Banya, A E Fletcher. (2011) Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension
CrossRef93
Jinping Wang, Jianlong Wu, Junfen Yang, Yihao Zhuang, Jialin Chen, Wenjing Qian, Jie Tian, Xiaoyan Chen, Dingping She, Fei Peng. (2011) Effects of pharmaceutical care interventions on blood pressure and medication adherence of patients with primary hypertension in China. Clinical Research and Regulatory Affairs 28:1, 1-6
CrossRef94
Robert H Fagard. (2011) Blood pressure lowering therapy in older and younger hypertensive patients. Journal of Hypertension 29:3, 440-442
CrossRef95
Nieves Ramírez-Duque, Antonia Mora-Rufete, M. Dolores Nieto-Martín, Máximo Bernabeu-Wittel, Alberto Escalera-Zalvide, María Sánchez-Ledesma, José Barbé Gil-Ortega, Lourdes Moreno-Gaviño, Virginia Rodríguez-Martínez, Carolina Luque-Amado. (2011) Riesgo cardiovascular y prescripción farmacológica en pacientes pluripatológicos. Hipertensión y Riesgo Vascular 28:2, 39-47
CrossRef96
Johji Kato, Naoto Yokota, Noboru Tamaki, Sumito Kariya, Toshihiro Kita, Takao Ayabe, Tanenao Eto, Kazuo Kitamura. (2011) Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension. Hypertension Research 34:3, 331-335
CrossRef97
Barbara J. Zarowitz. (2011) The ADA Focus on Diabetes 2011. Geriatric Nursing 32:2, 119-122
CrossRef98
Giuseppe Mancia, Guido Grassi. (2011) Impact of new clinical trials on recent guidelines on hypertension management. Annals of Medicine 43:2, 124-132
CrossRef99
M. Endres, P. U. Heuschmann, U. Laufs, A. M. Hakim. (2011) Primary prevention of stroke: blood pressure, lipids, and heart failure. European Heart Journal 32:5, 545-552
CrossRef100
Jan Basile, Simon Babazadeh, Michael Lillestol, Jaco Botha, Carol Yurkovic, Richard Weitzman. (2011) Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study. The Journal of Clinical Hypertension 13:3, 162-169
CrossRef101
J.M. Galcerán Gui. (2011) Nefroprotección y riesgo vascular: prevención del daño renal en la hipertensión arterial. Revista Clínica Española 211, 15-20
CrossRef102
David J Collier, Neil R Poulter, Björn Dahlöf, Peter S Sever, Hans Wedel, Jan Buch, Mark J Caulfield. (2011) Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial−Blood Pressure Lowering Arm (ASCOT-BPLA). Journal of Hypertension 29:3, 583-591
CrossRef103
Kay-Tee Khaw. 2011. Cardiovascular Risk Factors and Their Treatment in the Oldest Old. , 441-445.
CrossRef104
Michael Fu. (2011) Hypertension in the elderly: Where are we?. International Journal of Cardiology
CrossRef105
George Tsoukas, Sanjiv Anand, Kwang Yang. (2011) Dose-Dependent Antihypertensive Efficacy and Tolerability of Perindopril in a Large, Observational, 12-Week, General Practice-Based Study. American Journal Cardiovascular Drugs 11:1, 45-55
CrossRef106
Luke J. Benvenuto, Lawrence R. Krakoff. (2011) Morbidity and Mortality of Orthostatic Hypotension: Implications for Management of Cardiovascular Disease. American Journal of Hypertension 24:2, 135-144
CrossRef107
D. G. Le Couteur, S. J. Simpson. (2011) Adaptive Senectitude: The Prolongevity Effects of Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 66A:2, 179-182
CrossRef108
Davinia Ryan, Joseph Harbison. (2011) Stroke as a medical emergency in older people. Reviews in Clinical Gerontology 21:01, 45-54
CrossRef109
Martin Wehling. (2011) GUIDELINE-DRIVEN POLYPHARMACY IN ELDERLY, MULTIMORBID PATIENTS IS BASICALLY FLAWED: THERE ARE ALMOST NO GUIDELINES FOR THESE PATIENTS. Journal of the American Geriatrics Society 59:2, 376-377
CrossRef110
Yasuaki Dohi, Genjiro Kimura. (2011) Renal function and cardiovascular events during antihypertensive treatment in elderly patients. Aging Health 7:1, 59-63
CrossRef111
N. D. Weatherley, P. R. Jackson. (2011) The new Sheffield risk and benefit tables for the elderly. QJM 104:1, 3-12
CrossRef112
Francois Gueyffier, Marco I Perez, James M Wright, Ivanny Marchant, Vijaya M Musini, Theodora Bejan-Angoulvant. (2011) Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. Journal of Hypertension 29:1, 171-173
CrossRef113
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef114
Arkadiusz Siennicki-Lantz, Sölve Elmståhl. (2011) Phenomenon of declining blood pressure in elderly - high systolic levels are undervalued with Korotkoff method. BMC Geriatrics 11:1, 57
CrossRef115
Alexander G Logan. (2011) Hypertension in aging patients. Expert Review of Cardiovascular Therapy 9:1, 113-120
CrossRef116
Shinichi Nomoto, Yuka Nakanishi. (2011) Investigation of polypharmacy in late-stage elderly patients visiting a community hospital outpatient unit. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:3, 276-281
CrossRef117
Larry B. Goldstein, Ralph L. Sacco. 2011. Primary Prevention of Stroke. , 242-251.
CrossRef118
Philip A. Wolf, William B. Kannel. 2011. Epidemiology of Stroke. , 198-218.
CrossRef119
Diana G. Taekema, Andrea B. Maier, Rudi G.J. Westendorp, Anton J.M. de Craen. (2011) Higher Blood Pressure Is Associated With Higher Handgrip Strength in the Oldest Old. American Journal of Hypertension 24:1, 83-89
CrossRef120
Y. B
jot, M. Giroud, E. Touz
CrossRef121
Wilhelm Niebling. (2011) Evidenztransfer in die Praxis – Hindernisse und Barrieren. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 105:9, 646-651
CrossRef122
Kazuaki Shimamoto. (2011) Guideline for the managements of hypertension -Blood pressure control for the elderly hypertension. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:6, 648-650
CrossRef123
Vivencio Barrios, Carlos Escobar. (2010) Antihypertensive and organ-protective effects of benazepril. Expert Review of Cardiovascular Therapy 8:12, 1653-1671
CrossRef124
Jessica W. Weiss, Eric S. Johnson, Amanda Petrik, David H. Smith, Xiuhai Yang, Micah L. Thorp. (2010) Systolic Blood Pressure and Mortality Among Older Community-Dwelling Adults With CKD. American Journal of Kidney Diseases 56:6, 1062-1071
CrossRef125
J. Scholze. (2010) Isolierte systolische Hypertonie. Herz 35:8, 568-575
CrossRef126
Rahul Malhotra, Angelique Chan, Chetna Malhotra, Truls Østbye. (2010) Prevalence, awareness, treatment and control of hypertension in the elderly population of Singapore. Hypertension Research 33:12, 1223-1231
CrossRef127
P Campbell, N Ghuman, D Wakefield, L Wolfson, W B White. (2010) Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly. Journal of Human Hypertension 24:11, 749-754
CrossRef128
Mark A. Munger. (2010) Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus. Drugs & Aging 27:11, 871-883
CrossRef129
Ettore Malacco, Stefano Omboni, Massimo Volpe, Alberto Auteri, Alberto Zanchetti. (2010) Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. Journal of Hypertension 28:11, 2342-2350
CrossRef130
J. Wernecke, A. Friedl. (2010) Therapieziele beim geriatrischen Patienten. Der Diabetologe 6:7, 551-559
CrossRef131
L. K. Petersen, K. Christensen, J. Kragstrup. (2010) Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age and Ageing 39:6, 674-680
CrossRef132
Takahiro Ohara, William C Little. (2010) Evolving focus on diastolic dysfunction in patients with coronary artery disease. Current Opinion in Cardiology 25:6, 613-621
CrossRef133
Hiromi Rakugi, Toshio Ogihara, Yoshio Goto, Masao Ishii. (2010) Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: a per-protocol analysis of JATOS. Hypertension Research 33:11, 1124-1128
CrossRef134
M. Volpe, G. Tocci. (2010) Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrology Dialysis Transplantation 25:11, 3465-3471
CrossRef135
S.S. Andrade, J.B. Serro-Azul, A. Nussbacher, D. Giorgi, H. Pierri, O. Gebara, M. Wajngarten. (2010) DAYTIME SYSTOLIC BLOOD PRESSURE LOAD AND PREVIOUS STROKE PREDICT CARDIOVASCULAR EVENTS IN TREATED OCTOGENARIANS WITH HYPERTENSION. Journal of the American Geriatrics Society 58:11, 2232-2234
CrossRef136
A. Calderón, C. Escobar, V. Barrios. (2010) ¿Debemos modificar nuestra conducta terapéutica como consecuencia de la revisión de 2009 de la guía para el manejo de la hipertensión arterial de la ESH/ESC?. Revista Clínica Española 210:10, 511-516
CrossRef137
Masahiro Akishita. (2010) Strict vs. mild blood pressure control in the elderly. Hypertension Research 33:11, 1102-1103
CrossRef138
Bo Carlberg, Peter M. Nilsson. (2010) Hypertension in the Elderly: What Is the Goal Blood Pressure Target and How Can This Be Attained?. Current Hypertension Reports 12:5, 331-334
CrossRef139
Carl J. Pepine, Terry A. Jacobson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, James C. Stolzenbach, Laura A. Williams. (2010) Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology 33:10, 609-619
CrossRef140
Jean-Jacques Mourad, Sylvain Le Jeune, Anthony Pirollo, Clarisse Mourad, Yann Gaudouen, Marilucy Lopez-Sublet. (2010) Combinations of inhibitors of the renin–angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. Current Medical Research and Opinion 26:9, 2263-2276
CrossRef141
Dina Zekry, Gabriel Gold. (2010) Management of Mixed Dementia. Drugs & Aging 27:9, 715-728
CrossRef142
Rachel H. Mackey, Lewis H. Kuller. (2010) Blood Pressure and Cognitive Outcome. Current Cardiovascular Risk Reports 4:5, 369-375
CrossRef143
Antonio Cherubini, Susanna Del Signore, Joe Ouslander, Todd Semla, Jean-Pierre Michel. (2010) Fighting Against Age Discrimination in Clinical Trials. Journal of the American Geriatrics Society 58:9, 1791-1796
CrossRef144
Robert L. Talbert. (2010) Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. Journal of the American Pharmacists Association 50:5, e116-e125
CrossRef145
Stephen P. Fitzgerald, Nigel G. Bean. (2010) An Analysis of the Interactions Between Individual Comorbidities and Their Treatments—Implications for Guidelines and Polypharmacy. Journal of the American Medical Directors Association 11:7, 475-484
CrossRef146
R. Peters, N. Beckett, L. Burch, M.-C. de Vernejoul, L. Liu, J. Duggan, C. Swift, B. Gil-Extremera, A. Fletcher, C. Bulpitt. (2010) The effect of treatment based on a diuretic (indapamide) ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age and Ageing 39:5, 609-616
CrossRef147
K. J. J. van Hateren, G. W. D. Landman, N. Kleefstra, K. H. Groenier, A. M. Kamper, S. T. Houweling, H. J. G. Bilo. (2010) Lower blood pressure associated with higher mortality in elderly diabetic patients (ZODIAC-12). Age and Ageing 39:5, 603-609
CrossRef148
D A Duprez, M A Munger, J Botha, D L Keefe, A N Charney. (2010) Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial. Journal of Human Hypertension 24:9, 600-608
CrossRef149
Scott J. Denardo, Yan Gong, Wilmer W. Nichols, Franz H. Messerli, Anthony A. Bavry, Rhonda M. Cooper-DeHoff, Eileen M. Handberg, Annette Champion, Carl J. Pepine. (2010) Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy. The American Journal of Medicine 123:8, 719-726
CrossRef150
Pavittarpaul Dhesi, Robert D Willix, Anita Phan, Faramarz Tehrani, Daniel Daneshvar, Ernst R Schwarz. (2010) Heart failure in the elderly: diastolic heart failure, medical therapy, women and end-of-life care. Aging Health 6:4, 429-437
CrossRef151
T F Butt, R L Branch, L Beesley, U Martin. (2010) Managing hypertension in the very elderly: effect of adverse drug reactions (ADRs) on achieving targets. Journal of Human Hypertension 24:8, 514-518
CrossRef152
Vito Campese, Edward L. Schneider. (2010) Reevaluating the Use of Antihypertensive Medications, a First Step Toward Reducing Polypharmacy in Very Old Patients. The Journal of Clinical Hypertension 12:8, 621-624
CrossRef153
B Tangiisuran, MP Gozzoli, JG Davies, C Rajkumar. (2010) Adverse drug reactions in older people. Reviews in Clinical Gerontology 20:03, 246-259
CrossRef154
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef155
Michael J. Fischer, Ann M. O'Hare. (2010) Epidemiology of Hypertension in the Elderly With Chronic Kidney Disease. Advances in Chronic Kidney Disease 17:4, 329-340
CrossRef156
Sylvia Wassertheil-Smoller. (2010) Stroke in women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 419-425
CrossRef157
Gerard Devlin. (2010) Women and elderly: subgroups under-represented in clinical trials. Current Opinion in Cardiology 25:4, 335-339
CrossRef158
Paolo Verdecchia, Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Giuseppe Mancia, Gianpaolo Reboldi. (2010) Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. Journal of Hypertension 28:7, 1356-1365
CrossRef159
Philip A. Kithas, Mark A. Supiano. (2010) Hypertension and Chronic Kidney Disease in the Elderly. Advances in Chronic Kidney Disease 17:4, 341-347
CrossRef160
Theodora Bejan-Angoulvant, Mitra Saadatian-Elahi, James M Wright, Eleanor B Schron, Lars H Lindholm, Robert Fagard, Jan A Staessen, François Gueyffier. (2010) Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. Journal of Hypertension 28:7, 1366-1372
CrossRef161
Ritu K. Soni, Anna C. Porter, James P. Lash, Mark L. Unruh. (2010) Health-Related Quality of Life in Hypertension, Chronic Kidney Disease, and Coexistent Chronic Health Conditions. Advances in Chronic Kidney Disease 17:4, e17-e26
CrossRef162
Paula T Einhorn, Barry R Davis, Jackson T Wright, Mahboob Rahman, Paul K Whelton, Sara L Pressel. (2010) ALLHAT: still providing correct answers after 7 years. Current Opinion in Cardiology 25:4, 355-365
CrossRef163
Patricia Van der Niepen, Alain G. Dupont. (2010) Improved Blood Pressure Control in Elderly Hypertensive Patients. Drugs & Aging 27:7, 573-588
CrossRef164
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2010) Blood pressure lowering in the oldest old. Journal of Hypertension 28:7, 1373-1376
CrossRef165
Gianfranco Parati, Alessia Giglio, Laura Lonati, Maurizio Destro, Alessandra Rossi Ricci, Francesca Cagnoni, Claudio Pini, Achille Venco, Andrea Maria Maresca, Michela Monza, Anna Maria Grandi, Stefano Omboni. (2010) Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-group study. Clinical Therapeutics 32:7, 1270-1284
CrossRef166
Daniel T. Lackland. (2010) The Role of Combination Therapy for Hypertension After ACCOMPLISH. Current Cardiovascular Risk Reports 4:4, 251-255
CrossRef167
R. Peters, E. Pinto, N. Beckett, C. Swift, J. Potter, T. McCormack, M. Nunes, J. Grimley-Evans, A. Fletcher, C. Bulpitt. (2010) Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). Age and Ageing 39:4, 439-445
CrossRef168
Y. Bejot, J.-P. Neau, F. Woimant, P. Krolak-Salmon, A. Jacquin, P. Manckoundia, P. Pfitzenmeyer, G.V. Osseby, M. Giroud. (2010) Épidémiologie et perspectives évolutives des accidents vasculaires cérébraux du sujet âgé. Les cahiers de l'année gérontologique 2:2, 104-109
CrossRef169
Andrea Truncali, Tamara Dumanovsky, Harriet Stollman, Sonia Y. Angell. (2010) Keep on Track: A Volunteer-Run Community-Based Intervention to Lower Blood Pressure in Older Adults. Journal of the American Geriatrics Society 58:6, 1177-1183
CrossRef170
Ronald Otto, Regina E. Roller, Bernhard Iglseder, Peter Dovjak, Monika Lechleitner, Ulrike Sommeregger, Ursula Benvenuti-Falger, Birgit Böhmdorfer, Markus Gosch. (2010) Komplikationen durch Diuretikatherapie bei geriatrischen Patienten. Wiener Medizinische Wochenschrift 160:11-12, 276-280
CrossRef171
James E. Bailey, Jim Y. Wan, Jun Tang, Muhammad A. Ghani, William C. Cushman. (2010) Antihypertensive Medication Adherence, Ambulatory Visits, and Risk of Stroke and Death. Journal of General Internal Medicine 25:6, 495-503
CrossRef172
Alejandro de la Sierra. (2010) Blood pressure control in the hypertensive population. What else the doctor can do?. Journal of Hypertension 28:6, 1129-1130
CrossRef173
M. K. Shea, D. K. Houston, B. J. Nicklas, S. P. Messier, C. C. Davis, M. E. Miller, T. B. Harris, D. W. Kitzman, K. Kennedy, S. B. Kritchevsky. (2010) The Effect of Randomization to Weight Loss on Total Mortality in Older Overweight and Obese Adults: The ADAPT Study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65A:5, 519-525
CrossRef174
Dan R. Berlowitz, Stanley Franklin. (2010) The Clock Is Ticking: The Case for Achieving More Rapid Control of Hypertension. The Journal of Clinical Hypertension 12:5, 323-327
CrossRef175
P. van Vliet, A. M. Oleksik, D. van Heemst, A. J. M. de Craen, R. G. J. Westendorp. (2010) Dynamics of Traditional Metabolic Risk Factors Associate With Specific Causes of Death in Old Age. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65A:5, 488-494
CrossRef176
Vicente Giner Galvañ, María José Esteban Giner, Abdelaal Ragheb El Farra, Lirios Tomás Gil. (2010) Complicaciones inmediatas derivadas del tratamiento antihipertensivo. A propósito de los estudios MEDIDA y HYVET. Medicina Clínica 134:14, 657-659
CrossRef177
Julián Segura de La Morena, José Antonio García Donaire, Luis Miguel Ruilope Urioste. (2010) Nuevas estrategias terapéuticas para mejorar el control de la hipertensión arterial y simplificar la pauta de tratamiento farmacológico. Medicina Clínica 134:14, 635-642
CrossRef178
Ruo-Li Chen, Joyce S. Balami, Margaret M. Esiri, Liang-Kung Chen, Alastair M. Buchan. (2010) Ischemic stroke in the elderly: an overview of evidence. Nature Reviews Neurology 6:5, 256-265
CrossRef179
Félix Miguel García, María José Montero Alonso, Alejandra García Ortiz, Alejandro Merino Senovilla. (2010) Excesos clínicos de la conferencia de consenso sobre hipertensión arterial. Medicina Clínica 134:11, 514-515
CrossRef180
Patrice Darmon, Matthias J. Kaiser, Jürgen M. Bauer, Cornel C. Sieber, Claude Pichard. (2010) Restrictive diets in the elderly: Never say never again?. Clinical Nutrition 29:2, 170-174
CrossRef181
David Leibowitz, Michael Bursztyn, Jeremy M. Jacobs, Eliana Ein-Mor, Jochanan Stessman. (2010) High prevalence of left ventricular hypertrophy in octogenarian women: The Jerusalem Longitudinal Cohort Study. Blood Pressure 19:2, 86-91
CrossRef182
Zanfina Ademi, Danny Liew, Bruce Hollingsworth, Ph. Gabriel Steg, Deepak L. Bhatt, Christopher M. Reid. (2010) Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease. American Journal Cardiovascular Drugs 10:2, 85-94
CrossRef183
John B Kostis. (2010) Antihypertensive Therapy With CCB/ARB Combination in Older Individuals: Focus on Amlodipine/Valsartan Combination. American Journal of Therapeutics 17:2, 188-196
CrossRef184
Koopman Henk. (2010) Opsporing en behandeling van hypertensie bij 80-plussers. Huisarts en wetenschap 2010:2, 74-75
CrossRef185
E. S. Robinson, N. D. Fisher, J. P. Forman, G. C. Curhan. (2010) Physical Activity and Albuminuria. American Journal of Epidemiology 171:5, 515-521
CrossRef186
John E. Morley. (2010) Hypertension: Is It Overtreated in the Elderly?. Journal of the American Medical Directors Association 11:3, 147-152
CrossRef187
Toshiharu Ninomiya, Sophia Zoungas, Bruce Neal, Mark Woodward, Anushka Patel, Vlado Perkovic, Alan Cass, Mark Cooper, Diederick Grobbee, Pavel Hamet, Stephen Harrap, Lisheng Liu, Giuseppe Mancia, Carl-Erik Mogensen, Neil Poulter, Anthony Rodgers, Bryan Williams, Stephen MacMahon, John Chalmers. (2010) Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension1
CrossRef188
Peter M Rothwell. (2010) Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. The Lancet 375:9718, 938-948
CrossRef189
Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 25:3, 261-269
CrossRef190
Stanley S. Franklin. (2010) Isolated systolic hypertension and the J-curve of cardiovascular disease risk. Artery Research 4:1, 1-6
CrossRef191
T D Szucs, B Waeber, Y Tomonaga. (2010) Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective. Journal of Human Hypertension 24:2, 117-123
CrossRef192
M. T. Vidan, H. Bueno, Y. Wang, G. Schreiner, J. S. Ross, J. Chen, H. M. Krumholz. (2010) The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. European Journal of Heart Failure 12:2, 148-155
CrossRef193
Farhan Aslam, Attiya Haque, Joseph V. Agostini, Yun Wang, JoAnne M. Foody. (2010) Hypertension Prevalence and Prescribing Trends in Older US Adults: 1999-2004. The Journal of Clinical Hypertension 12:2, 75-81
CrossRef194
Hiromi Rakugi. (2010) Management of elderly hypertension. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:6, 522-525
CrossRef195
Masako Takeshita, Mariko Miyao, Yuzo Mizuno. (2010) Thiazide diuretics for hypertensive treatment induced severe hyponatremia with consciousness disturbance in two elderly cases. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:3, 257-261
CrossRef196
Massimo Motta, Ettore Bennati, Elisabeth Cardillo, Laura Ferlito, Michela Passamonte, Marco Vacante, Mariano Malaguarnera. (2010) A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. Archives of Gerontology and Geriatrics 50:1, 105-109
CrossRef197
Hiromi Rakugi. (2010) JSH2009 for the management of hypertension in the elderly: A perspective of geriatric medicine. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:3, 180-183
CrossRef198
Siri Kristjansson, Torgeir Wyller. (2010) Avslutning av forebyggende legemiddelbruk hos eldre. Tidsskrift for Den norske legeforening 130:17, 1726-1728
CrossRef199
Sanjiv J. Shah. (2010) Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery Disease. Current Treatment Options in Cardiovascular Medicine 12:1, 58-75
CrossRef200
Kwang-Il Kim, Cheol-Ho Kim. (2010) Recent Advance in the Treatment of Hypertension. Journal of the Korean Medical Association 53:3, 208
CrossRef201
K. Ali, E. Ormerod, C. Rajkumar. (2010) Hyper- or hypotension in an older population: where do clinicians stand?. Age and Ageing 39:1, 4-5
CrossRef202
Toshio Kushiro. (2010) Practical know-how in treating elderly patients with hypertension. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:2, 123-126
CrossRef203
Ivy Poon, Lincy S Lal, Marvella E Ford, Ursula K Braun. (2010) Racial/Ethnic Differences in Blood Pressure Control and Medication Utilization in a Cohort of Older Veterans with Dementia. American Journal of Therapeutics 17:1, 34-41
CrossRef204
Athanase Benetos, Severine Buatois, Paolo Salvi, Francesca Marino, Olivier Toulza, Delphine Dubail, Patrick Manckoundia, Filippo Valbusa, Yves Rolland, Olivier Hanon, Sylvie Gautier, Darko Miljkovic, Francis Guillemin, Mauro Zamboni, Carlos Labat, Christine Perret-Guillaume. (2010) Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study. Journal of Hypertension 28:1, 41-50
CrossRef205
Flávio Danni Fuchs. (2010) Corporate influence over planning and presentation of clinical trials: beauty and the beast. Expert Review of Cardiovascular Therapy 8:1, 7-9
CrossRef206
Ann Thompson, Bill Semchuk, Norman R. C. Campbell, Janusz Kaczorowski, Ross T. Tsuyuki. (2010) Hypertension guidelines for pharmacists: 2009 update. Canadian Pharmacists Journal 143:1, 20-27
CrossRef207
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef208
Brigitte M. Baumann, John J. Cienki, David M. Cline, Darcy Egging, Jill F. Lehrmann, Paula Tanabe. (2009) Evaluation, management, and referral of elderly emergency department patients with elevated blood pressure. Blood Pressure Monitoring 14:6, 251-256
CrossRef209
I. Maeve Rea, Phyo K. Myint, Heiko Mueller, Anne Murphy, G. Pooler R. Archbold, Helene McNulty, Chris C. Patterson. (2009) Nature or nurture; BMI and blood pressure at 90. Findings from the Belfast Elderly Longitudinal Free-living Aging STudy (BELFAST). AGE 31:4, 261-267
CrossRef210
Silvia Bustacchini, Andrea Corsonello, Graziano Onder, Enrico Eugenio Guffanti, Flavio Marchegiani, Angela Marie Abbatecola, Fabrizia Lattanzio. (2009) Pharmacoeconomics and Aging. Drugs & Aging 26:Supplement 1, 75-87
CrossRef211
Tomonari Okada, Toshiyuki Nakao, Hiroshi Matsumoto, Yume Nagaoka, Ryo Tomaru, Hideaki Iwasawa, Toshikazu Wada. (2009) Prognostic significance of home blood pressure control on renal and cardiovascular outcomes in elderly patients with chronic kidney disease. Hypertension Research 32:12, 1123-1129
CrossRef212
Bryan Williams. (2009) The Year in Hypertension. Journal of the American College of Cardiology 55:1, 65-73
CrossRef213
(2009) Evidence-based Practice Guideline for the Treatment of CKD. Clinical and Experimental Nephrology 13:6, 537-566
CrossRef214
Cinzia Maraldi, Fabrizia Lattanzio, Graziano Onder, Massimo Gallerani, Silvia Bustacchini, Giuseppe De Tommaso, Stefano Volpato. (2009) Variability in the Prescription of Cardiovascular Medications in Older Patients. Drugs & Aging 26:Supplement 1, 41-51
CrossRef215
Stefano Omboni, Ettore Malacco, Gianfranco Parati. (2009) Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions. Cardiovascular Therapeutics 27:4, 275-288
CrossRef216
Jerónimo Jurado Campos, Jacint A. Caula Ros, Josep M. Hernández Anguera, Dolors Juvinyà Canal, José M. Pou Torelló. (2009) La supresión de la educación especializada empeora el control metabólico en diabetes tipo 2. Atención Primaria 41:12, 681-687
CrossRef217
Ernst, Michael E., Moser, Marvin, . (2009) Use of Diuretics in Patients with Hypertension. New England Journal of Medicine 361:22, 2153-2164
Full Text218
Peter Kriekard, S. Michael Gharacholou, Eric D. Peterson. (2009) Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. Clinics in Geriatric Medicine 25:4, 745-755
CrossRef219
José L. Llisterri, Francisco J. Alonso, Manuel Gorostidi, Cristina Sierra, Alejandro de La Sierra, José R. Banegas, Julián Segura, Javier Sobrino, Juan J. De La Cruz, Felipe Madruga, Pedro Aranda, Josep Redon, Luis M. Ruilope. (2009) Diferencias entre el control clínico y ambulatorio de la hipertensión arterial en pacientes muy ancianos. Proyecto CARDIORISC–MAPAPRES. Medicina Clínica 133:20, 769-776
CrossRef220
C. Sirois, J. Moisan, P. Poirier, J. Couture, J.-P. Gregoire. (2009) Association between age and the initiation of antihypertensive, lipid lowering and antiplateletet medications in elderly individuals newly treated with antidiabetic drugs. Age and Ageing 38:6, 741-745
CrossRef221
Wilbert S. Aronow. (2009) Hypertension in the Elderly. Clinics in Geriatric Medicine 25:4, 579-590
CrossRef222
Nerses Sanossian, Bruce Ovbiagele. (2009) Prevention and management of stroke in very elderly patients. The Lancet Neurology 8:11, 1031-1041
CrossRef223
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef224
Lucy Y. Wang, Eric B. Larson, Joshua A. Sonnen, Jane B. Shofer, Wayne McCormick, James D. Bowen, Thomas J. Montine, Ge Li. (2009) Blood Pressure and Brain Injury in Older Adults: Findings from a Community-Based Autopsy Study. Journal of the American Geriatrics Society 57:11, 1975-1981
CrossRef225
Wilbert S. Aronow. (2009) Data are Needed on Target Blood Pressure for Elderly People. Journal of the American Geriatrics Society 57:11, 2177-2177
CrossRef226
Fernando Tornero Molina. (2009) Peculiaridades de la monitorización ambulatoria de la presión arterial en el paciente anciano. Medicina Clínica 133:20, 787-788
CrossRef227
Lisheng Liu, Zengwu Wang, Lansheng Gong, Yuqing Zhang, Lutgarde Thijs, Jan A Staessen, Jiguang Wang. (2009) Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research 32:11, 1032-1040
CrossRef228
Basil O. Burney, George L. Bakris. (2009) Hypertension and its Management in the Elderly. Seminars in Nephrology 29:6, 604-609
CrossRef229
Andrea Ungar, Mauro Di Bari, Niccolò Marchionni. (2009) Response Letter to Drs. Aronow and Kim. Journal of the American Geriatrics Society 57:11, 2177-2178
CrossRef230
Vijaya M Musini, Aaron M Tejani, Ken Bassett, James M Wright, Vijaya M Musini. 2009. Pharmacotherapy for hypertension in the elderly. .
CrossRef231
Bernadette McGuinness, Stephen Todd, Peter Passmore, Roger Bullock, Bernadette McGuinness. 2009. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. .
CrossRef232
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2009) Clinical Update on Nursing Home Medicine: 2009. Journal of the American Medical Directors Association 10:8, 530-553
CrossRef233
Michael J Fischer. (2009) Hypertension treatment and management concerns in the elderly. Aging Health 5:5, 683-699
CrossRef234
Osvaldo P. Almeida, Janine Calver, Konrad Jamrozik, Graeme J. Hankey, Leon Flicker. (2009) Obesity and Metabolic Syndrome Increase the Risk of Incident Depression in Older Men: The Health in Men Study. American Journal of Geriatric Psychiatry 17:10, 889-898
CrossRef235
Ruth Peters, Ruth Poulter, Nigel Beckett, Françoise Forette, Robert Fagard, John Potter, Cameron Swift, Craig Anderson, Astrid Fletcher, Christopher J Bulpitt. (2009) Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. Journal of Hypertension 27:10, 2055-2062
CrossRef236
David J. Hyman, George E. Taffet. (2009) Blood pressure control in the elderly: Can you have too much of a good thing?. Current Hypertension Reports 11:5, 337-342
CrossRef237
Katsuyuki Ando, Masashi Isshiki, Katsutoshi Takahashi. (2009) Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. Hypertension Research 32:9, 748-752
CrossRef238
J. J. Mourad, S. Le Jeune. (2009) Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients. Current Medical Research and Opinion 25:9, 2271-2280
CrossRef239
Z. D. Kobalava, Y. V. Kotovskaya, S. V. Villevalde, V. S. Moiseev. (2009) Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 study. Current Medical Research and Opinion 25:9, 2229-2237
CrossRef240
Ali Yazdanyar, Anne B. Newman. (2009) Evolving concepts of cardiovascular disease prevention in older adults. Current Cardiovascular Risk Reports 3:5, 366-373
CrossRef241
Gustavo C Rodríguez-Roca, Vicente Pallarés-Carratalá, Francisco J Alonso-Moreno, Carlos Escobar-Cervantes, Vivencio Barrios, José L Llisterri, Francisco Valls-Roca, José L Carrasco-Martín, José M Fernández-Toro, José R Banegas. (2009) Blood pressure control and physicians’ therapeutic behavior in a very elderly Spanish hypertensive population. Hypertension Research 32:9, 753-758
CrossRef242
Alan H. Gradman. (2009) Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. Drugs & Aging 26:9, 751-767
CrossRef243
Zanfina Ademi, Danny Liew, Derek Chew, Greg Conner, Louise Shiel, Mark Nelson, Ash Soman, Gabriel Steg, Deepak L. Bhatt, Christopher Reid, . (2009) Drug Treatment and Cost of Cardiovascular Disease in Australia. Cardiovascular Therapeutics 27:3, 164-172
CrossRef244
A. Cohen-Solal, D. Kotecha, D. J van Veldhuisen, D. Babalis, M. Bohm, A. J. Coats, M. Roughton, P. Poole-Wilson, L. Tavazzi, M. Flather, . (2009) Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure 11:9, 872-880
CrossRef245
Emmanuelle Duron, Anne-Sophie Rigaud, Delphine Dubail, Shima Mehrabian, Florence Latour, Marie-Laure Seux, Olivier Hanon. (2009) Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer's Disease. American Journal of Hypertension 22:9, 1020-1024
CrossRef246
Roxana Oprisiu-Fournier, Sébastien Faure, Hakim Mazouz, Florent Boutitie, Jean-Marie Serot, Jean-Michel Achard, Olivier Godefroy, Olivier Hanon, Mohammed Temmar, Adriana Albu, Svend Strandgaard, Jiguang Wang, Sandra E Black, Albert Fournier. (2009) Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?. Expert Review of Neurotherapeutics 9:9, 1289-1305
CrossRef247
R. Peters, N. Beckett, M. Geneva, M. Tzekova, F. H. Lu, R. Poulter, N. Gainsborough, B. Williams, M.-C. de Vernejoul, A. Fletcher, C. Bulpitt. (2009) Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. Age and Ageing 38:5, 521-527
CrossRef248
Albert Fournier, Roxana Oprisiu-Fournier, Jean-Marie Serot, Olivier Godefroy, Jean-Michel Achard, Sebastien Faure, Hakim Mazouz, Mohamed Temmar, Adriana Albu, Régis Bordet, Olivier Hanon, François Gueyffier, Jiguang Wang, Sandra Black, Naoyuki Sato. (2009) Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics 9:9, 1413-1431
CrossRef249
Marie Therese Cooney, Alexandra L. Dudina, Ian M. Graham. (2009) Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk. Journal of the American College of Cardiology 54:14, 1209-1227
CrossRef250
Chobanian, Aram V., . (2009) The Hypertension Paradox — More Uncontrolled Disease despite Improved Therapy. New England Journal of Medicine 361:9, 878-887
Full Text251
Dean J. Kereiakes, Joel Neutel, Kathy A. Stoakes, William F. Waverczak, Jianbo Xu, Ali Shojaee, Robert Dubiel. (2009) The Effects of an Olmesartan Medoxomil-Based Treatment Algorithm on 24-Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older. The Journal of Clinical Hypertension 11:8, 411-421
CrossRef252
Christos Chatzikyrkou, Jan Menne, Hermann Haller. (2009) Hypertonologie 2007–2008. Medizinische Klinik 104:8, 614-621
CrossRef253
Maria Czarina Acelajado, Suzanne Oparil. (2009) Hypertension in the Elderly. Clinics in Geriatric Medicine 25:3, 391-412
CrossRef254
Ruth Peters, Nigel Beckett. (2009) Hypertension, dementia, and antihypertensive treatment: Implications for the very elderly. Current Hypertension Reports 11:4, 277-282
CrossRef255
Alberto Zanchetti. (2009) Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. Journal of Hypertension 27:8, 1509-1520
CrossRef256
Michael A. Chen. (2009) Heart Failure with Preserved Ejection Fraction in Older Adults. The American Journal of Medicine 122:8, 713-723
CrossRef257
Suissa, Samy, . (2009) Calculation of Number Needed to Treat. New England Journal of Medicine 361:4, 424-425
Full Text258
James M Wright, Vijaya M Musini, James M Wright. 2009. First-line drugs for hypertension. .
CrossRef259
T. E. Strandberg, A. Y. Strandberg, V. V. Salomaa, K. H. Pitkala, R. S. Tilvis, J. Sirola, T. A. Miettinen. (2009) Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long-term follow-up in men. European Heart Journal 30:14, 1720-1727
CrossRef260
Edo Richard, Esther Van den Heuvel, Eric P. Moll van Charante, Lenny Achthoven, Marinus Vermeulen, Patrick J. Bindels, Willem A. Van Gool. (2009) Prevention of Dementia by Intensive Vascular Care (PreDIVA). Alzheimer Disease & Associated Disorders 23:3, 198-204
CrossRef261
Nigel S. Beckett, Dean J. Noimark. (2009) Hypertension therapy in the oldest patients. Current Cardiovascular Risk Reports 3:4, 239-246
CrossRef262
Charlotta Ljungman, Lena Mortensen, Thomas Kahan, Karin Manhem. (2009) Treatment of Mild to Moderate Hypertension by Gender Perspective: A Systematic Review. Journal of Women's Health 18:7, 1049-1062
CrossRef263
Siobhan HM Brown, Ahmed H Abdelhafiz. (2009) Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. Therapy 6:4, 515-529
CrossRef264
John E. Morley. (2009) Polypharmacy in the Nursing Home. Journal of the American Medical Directors Association 10:5, 289-291
CrossRef265
M. Dieterich, G. F. Hamann. (2009) Bericht vom NeuroUpdate der Med-Update-Reihe in Wiesbaden (13./14.02.09). Der Nervenarzt 80:6, 720-724
CrossRef266
José R González-Juanatey. (2009) The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice. Journal of Hypertension 27:Suppl 2, S32-S35
CrossRef267
U.-M. Vischer, B. Bauduceau, I. Bourdel-Marchasson, J.-F. Blickle, T. Constans, A. Fagot-Campagna, E. Kaloustian, V. Lassman-Vague, P. Lecomte, D. Simon, D. Tessier, C. Verny, J. Doucet. (2009) A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes & Metabolism 35:3, 168-177
CrossRef268
Flávio Danni Fuchs. (2009) Diuretics: still essential drugs for the management of hypertension. Expert Review of Cardiovascular Therapy 7:6, 591-598
CrossRef269
Hisatomi Arima. (2009) Blood pressure-lowering treatment for primary and secondary prevention of different types of stroke. Expert Review of Cardiovascular Therapy 7:6, 627-636
CrossRef270
Danielle Cooney, Kristina Pascuzzi. (2009) Polypharmacy in the Elderly: Focus on Drug Interactions and Adherence in Hypertension. Clinics in Geriatric Medicine 25:2, 221-233
CrossRef271
Clara Rosso, Josep M. Arnau. (2009) Tratamiento de la hipertensión en pacientes mayores de 80 años. Revista Española de Geriatría y Gerontología 44:3, 162-164
CrossRef272
Krishna K. Gaddam, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura. (2009) Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America 93:3, 665-680
CrossRef273
Ramiro A Sanchez, Miryam Ayala, Hugo Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio López Jaramillo, Ayrton Brandao, Gloria Valdes, Luis Alcocer, Mario Bendersky, Agustín José Ramirez, Alberto Zanchetti. (2009) Latin American guidelines on hypertension*. Journal of Hypertension 27:5, 905-922
CrossRef274
Arash Rashidi, Jackson T. Wright. (2009) Drug Treatment of Hypertension in Older Hypertensives. Clinics in Geriatric Medicine 25:2, 235-244
CrossRef275
Norman R.C. Campbell, Nadia A. Khan, Michael D. Hill, Guy Tremblay, Marcel Lebel, Janusz Kaczorowski, Finlay A. McAlister, Richard Z. Lewanczuk, Sheldon Tobe. (2009) 2009 Canadian Hypertension Education Program recommendations: The scientific summary – an annual update. Canadian Journal of Cardiology 25:5, 271-277
CrossRef276
Dae Hyun Kim, Ihab Hajjar. (2009) BLOOD PRESSURE AND MORTALITY IN VERY OLD PEOPLE. Journal of the American Geriatrics Society 57:5, 940-941
CrossRef277
Nadia A. Khan, Brenda Hemmelgarn, Robert J. Herman, Chaim M. Bell, Jeff L. Mahon, Lawrence A. Leiter, Simon W. Rabkin, Michael D. Hill, Raj Padwal, Rhian M. Touyz, Pierre Larochelle, Ross D. Feldman, Ernesto L. Schiffrin, Norman R.C. Campbell, Gordon Moe, Ramesh Prasad, Malcolm O. Arnold, Tavis S. Campbell, Alain Milot, James A. Stone, Charlotte Jones, Richard I. Ogilvie, Pavel Hamet, George Fodor, George Carruthers, Kevin D. Burns, Marcel Ruzicka, Jacques deChamplain, George Pylypchuk, Robert Petrella, Jean-Martin Boulanger, Luc Trudeau, Robert A. Hegele, Vincent Woo, Phil McFarlane, Michel Vallée, Jonathan Howlett, Simon L. Bacon, Patrice Lindsay, Richard E. Gilbert, Richard Z. Lewanczuk, Sheldon Tobe. (2009) The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology 25:5, 287-298
CrossRef278
Ruth Peters. (2009) The prevention of dementia. International Journal of Geriatric Psychiatry 24:5, 452-458
CrossRef279
Alberto Zanchetti, Guido Grassi, Giuseppe Mancia. (2009) When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. Journal of Hypertension 27:5, 923-934
CrossRef280
Luis Castilla Guerra, María del Carmen Fernández Moreno, Jesús Álvarez Suero, Encarnación Martín Pérez. (2009) Hipertensión en los muy ancianos: ¿tratar o no tratar?, esa ya no es la cuestión. Revista Española de Geriatría y Gerontología 44:3, 165-166
CrossRef281
William J. Mosley, Donald M. Lloyd-Jones. (2009) Epidemiology of Hypertension in the Elderly. Clinics in Geriatric Medicine 25:2, 179-189
CrossRef282
Mohammed A. Rafey. (2009) Resistant Hypertension in the Elderly. Clinics in Geriatric Medicine 25:2, 289-301
CrossRef283
Maha A. Mohamed, Matthew R. Weir. (2009) Renin Angiotensin System Inhibition in the Older Person: A Review. Clinics in Geriatric Medicine 25:2, 245-257
CrossRef284
Mary V. Corrigan, Muralidhar Pallaki. (2009) General Principles of Hypertension Management in the Elderly. Clinics in Geriatric Medicine 25:2, 207-212
CrossRef285
Sean P. Kennelly, B.A. Lawlor, R.A. Kenny. (2009) Blood pressure and the risk for dementia—A double edged sword. Ageing Research Reviews 8:2, 61-70
CrossRef286
Marvin Moser. (2009) The More Things Change, the More They Remain the Same. The Journal of Clinical Hypertension 11:4, 171-174
CrossRef287
Alberto Zanchetti, Giuseppe Mancia, Henry R Black, Suzanne Oparil, Bernard Waeber, Roland E Schmieder, George L Bakris, Franz H Messerli, Sverre E Kjeldsen, Luis M Ruilope. (2009) Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. Journal of Hypertension 27:4, 673-679
CrossRef288
Jasper J Brugts, Roberto Ferrari, Maarten L Simoons. (2009) Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Review of Cardiovascular Therapy 7:4, 345-360
CrossRef289
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2009) The Year in Atherothrombosis. Journal of the American College of Cardiology 53:15, 1326-1337
CrossRef290
Christos Chatzikyrkou, Hermann Haller, Jan Menne. (2009) Fixed-dose combination of lercanidipine/enalapril in the treatment of hypertension in the elderly. Aging Health 5:2, 141-149
CrossRef291
Paul E. Drawz, Cristina Bocirnea, Katarina B. Greer, Julian Kim, Florian Rader, Patrick Murray. (2009) Hypertension Guideline Adherence Among Nursing Home Patients. Journal of General Internal Medicine 24:4, 499-503
CrossRef292
R. Kreutz. (2009) Besonderheiten der Pharmakotherapie beim älteren Hypertoniker. Der Internist 50:4, 442-454
CrossRef293
Ruth Peters, Nigel Beckett, Françoise Forette, Jaakko Tuomilehto, Craig Ritchie, Ivan Walton, Adam Waldman, Robert Clarke, Ruth Poulter, Astrid Fletcher, Christopher Bulpitt. (2009) Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. International Psychogeriatrics 21:02, 359
CrossRef294
Norman M. Kaplan. (2009) Hypertension: Combination therapy for hypertension. Nature Reviews Cardiology 6:4, 270-271
CrossRef295
J. Schrader. (2009) Schlaganfall und Hypertonie. Der Internist 50:4, 423-432
CrossRef296
Carla Sueta Dupree. (2009) Primary prevention of heart failure: what is the evidence?. Current Opinion in Cardiology 24:2, 142-147
CrossRef297
Dmitry Abramov, Huai Cheng. (2009) CONTROVERSY IN TREATING THE OLDEST OLD WITH HYPERTENSION: IS THE HYPERTENSION IN THE VERY ELDERLY TRIAL THE FINAL ANSWER?. Journal of the American Geriatrics Society 57:3, 570-571
CrossRef298
Martin Wehling. (2009) MULTIMORBIDITY AND POLYPHARMACY: HOW TO REDUCE THE HARMFUL DRUG LOAD AND YET ADD NEEDED DRUGS IN THE ELDERLY? PROPOSAL OF A NEW DRUG CLASSIFICATION: FIT FOR THE AGED. Journal of the American Geriatrics Society 57:3, 560-561
CrossRef299
Camille P. Vaughan, Theodore M. Johnson. (2009) Editorial Comment. Urology 73:3, 554
CrossRef300
Csaba Farsang, Lisa Naditch-Brule, Angelo Avogaro, Jan Östergren, Paolo Verdecchia, Aldo Maggioni, Philippe van de Borne, Robert Lins, Alexandre Roca-Cusachs. (2009) Where Are We With the Management of Hypertension? From Science to Clinical Practice. The Journal of Clinical Hypertension 11:2, 66-73
CrossRef301
Eric B. Larson. (2009) Evidence, Guidelines, Performance Incentives, Complexity, and Old People: A Clinician's Dilemma. Journal of the American Geriatrics Society 57:2, 353-354
CrossRef302
Jonathan G. Howlett, Robert S. McKelvie, J Malcolm O. Arnold, Jeannine Costigan, Paul Dorian, Anique Ducharme, Estrellita Estrella-Holder, Justin A. Ezekowitz, Nadia Giannetti, Haissam Haddad, George A. Heckman, Anthony M. Herd, Debra Isaac, Philip Jong, Simon Kouz, Peter Liu, Elizabeth Mann, Gordon W. Moe, Ross T. Tsuyuki, Heather J. Ross, Michel White. (2009) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Canadian Journal of Cardiology 25:2, 85-105
CrossRef303
José R. Banegas, Albert Jovell, Benjamín Abarca, Manuel Aguilar Diosdado, Luis Aguilera, Pedro Aranda, Vicente Bertoméu, Pedro Capilla, Pedro Conthe, Fernando De Álvaro, Antonio Fernández-Pro, Xavier Formiguera, Jesús Frías, Lucía Guerrero, José L. Llisterri, José M. Lobos, Juan F. Macías, Ángel L. Martín De Francisco, Jesús Millán, Juan C. Morales, Vicente Palomo, Alex Roca-Cusachs, Javier Román, Carlos Sanchis, Antonio Sarriá, Julián Segura, Álex De La Sierra, Luis Verde, Julio Zarco, Luis M. Ruilope. (2009) Hipertensión arterial y política de salud en España. Medicina Clínica 132:6, 222-229
CrossRef304
Pilar Mazón-Ramos, Alberto Cordero-Fort, Juan Quiles-Granado, Josep Guindo-Soldevila. (2009) Temas de actualidad en hipertensión arterial y diabetes. Revista Española de Cardiología 62, 14-27
CrossRef305
Marvin Moser. (2009) Physician or Clinical Inertia: What Is It? Is It Really a Problem? And What Can Be Done About It?. The Journal of Clinical Hypertension 11:1, 1-4
CrossRef306
Hiroshi Nakano. (2009) Clinical Feature and Treatment of Hypertension in Patients 75 Years or Older. Nihon Ika Daigaku Igakkai Zasshi 5:4, 207-210
CrossRef307
H. F. McIntyre. (2009) Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation. International Journal of Clinical Practice 63:1, 7-14
CrossRef308
Hiromi Rayugi. (2009) CASE-J: A large-scale clinical trial in hypertensive patients. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 46:1, 29-32
CrossRef309
Wilbert S. Aronow. (2009) Treating Hypertension in Older Adults. Drug Safety 32:2, 111-118
CrossRef310
Shuntaro Kagiyama, Yutaka Takata, Toshihiro Ansai, Kiyoshi Matsumura, Inho Soh, Shuji Awano, Kazuo Sonoki, Akihiro Yoshida, Takehiro Torisu, Tomoko Hamasaki, Ikuo Nakamichi, Tadamichi Takehara, Mitsuo Iida. (2009) Does Decreased Diastolic Blood Pressure Associate with Increased Mortality in 80-Year-Old Japanese?. Clinical and Experimental Hypertension 31:8, 639-647
CrossRef311
Jennifer G. Robinson. (2009) Is a statin as part of a polypill the answer?. Current Atherosclerosis Reports 11:1, 15-22
CrossRef312
Taishiro Chikamori. (2009) Management of ischemic heart disease in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 46:5, 391-394
CrossRef313
Cheryl D. Bushnell, Cathleen S. Colón-Emeric. (2009) Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs & Aging 26:3, 209-230
CrossRef314
Chobanian, Aram V., . (2008) Does It Matter How Hypertension Is Controlled?. New England Journal of Medicine 359:23, 2485-2488
Full Text315
Jamerson, Kenneth, Weber, Michael A., Bakris, George L., Dahlöf, Björn, Pitt, Bertram, Shi, Victor, Hester, Allen, Gupte, Jitendra, Gatlin, Marjorie, Velazquez, Eric J., . (2008) Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal of Medicine 359:23, 2417-2428
Full Text316
Kenichiro Shimizu, Nobuyoshi Hirose, Michiyo Takayama, Yasumichi Arai, Yasuyuki Gondo, Yoshinori Ebihara, Ken Yamamura, Susumu Nakazawa, Hiroki Inagaki, Yukie Masui, Koji Kitagawa. (2008) Relationship between physical and cognitive function, blood pressure and serum lipid concentration in centenarians. Geriatrics & Gerontology International 8:4, 300-302
CrossRef317
Joel Handler. (2008) Treatment of Systolic Hypertension and Severe Asymptomatic Aortic Regurgitation. The Journal of Clinical Hypertension 10:12, 951-955
CrossRef318
Leon Flicker. (2008) Vascular factors in geriatric psychiatry: time to take a serious look. Current Opinion in Psychiatry 21:6, 551-554
CrossRef319
Suresh Krishnamoorthy, Gregory YH Lip. (2008) Hypertension, stroke and the impact of atrial fibrillation. Expert Review of Cardiovascular Therapy 6:10, 1287-1289
CrossRef320
Albert J. Finestone. (2008) Reprise: “One Size May Not Fit All”. The Journal of Clinical Hypertension 10:11, 887-887
CrossRef321
J. García Puig, B. Gil Extremera. (2008) ¿Debemos tratar la hipertensión arterial en el muy anciano?. Revista Clínica Española 208:10, 481-482
CrossRef322
Tatjana Rundek, Ralph L. Sacco. (2008) Risk Factor Management to Prevent First Stroke. Neurologic Clinics 26:4, 1007-1045
CrossRef323
Shuntaro Kagiyama, Kiyoshi Matsumura, Toshihiro Ansai, Inho Soh, Yutaka Takata, Shuji Awano, Kazuo Sonoki, Akihiro Yoshida, Tadamichi Takehara, Mitsuo Iida. (2008) Chronic Kidney Disease Increases Cardiovascular Mortality in 80-Year-Old Subjects in Japan. Hypertension Research 31:11, 2053-2058
CrossRef324
D Gareth Beevers. (2008) Hypertension in practice: towards the year 2010. Therapy 5:6, 759-771
CrossRef325
E. Wahlberg. (2008) Hypertension in the Very Elderly - A Call to Improve Blood Pressure Management of Our PAD Patients. European Journal of Vascular and Endovascular Surgery 36:4, 407-408
CrossRef326
Eberhard Ritz. (2008) Is it beneficial to treat hypertension in patients aged 80 years or older?. Nature Clinical Practice Nephrology 4:10, 526-527
CrossRef327
Lena Molander, Hugo Lövheim, Tove Norman, Peter Nordström, Yngve Gustafson. (2008) Lower Systolic Blood Pressure Is Associated with Greater Mortality in People Aged 85 and Older. Journal of the American Geriatrics Society 56:10, 1853-1859
CrossRef328
NORRA MACREADY. (2008) Expert Picks on Whatʼs Most Noteworthy from Clinical Trials on Stroke Interventions. Neurology Today 8:20, 20-21
CrossRef329
Cristina Sierra, Alfonso López-Soto, Antonio Coca. (2008) La hipertensión arterial en la población anciana. Revista Española de Geriatría y Gerontología 43, 53-59
CrossRef330
Blas Gil Extremera. (2008) Tratamiento del paciente de 80 o más años con hipertensión arterial. Medicina Clínica 131:14, 538-539
CrossRef331
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2008) Clinical Update on Nursing Home Medicine: 2008. Journal of the American Medical Directors Association 9:7, 460-475
CrossRef332
L. Michael Prisant. (2008) Now or Never: Optimal Antihypertensive Therapy in the Elderly. Preventive Cardiology 11:4, 201-209
CrossRef333
Wilbert S Aronow. (2008) Older age should not be a barrier to the treatment of hypertension. Nature Clinical Practice Cardiovascular Medicine 5:9, 514-515
CrossRef334
Barry A Franklin, Justin E Trivax, Thomas E Vanhecke. (2008) New insights in preventive cardiology and cardiac rehabilitation. Current Opinion in Cardiology 23:5, 477-486
CrossRef335
Daniel A. Duprez. (2008) The Reply. The American Journal of Medicine 121:9, e23
CrossRef336
Athanase Benetos. (2008) Arterial stiffness and systolic hypertension: Determinants, assessment, and clinical consequences. Current Cardiovascular Risk Reports 2:5, 410-415
CrossRef337
(2008) Treatment of Hypertension in the Elderly. New England Journal of Medicine 359:9, 971-974
Full Text338
L. Zhao, X. J. Hu, S. W. Lagakos. (2008) Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach. Biostatistics 10:2, 310-323
CrossRef339
J. F. E. Mann. (2008) What's new in hypertension 2008?. Nephrology Dialysis Transplantation 24:1, 38-42
CrossRef340
Ruth Peters, Nigel Beckett, Francoise Forette, Jaakko Tuomilehto, Robert Clarke, Craig Ritchie, Adam Waldman, Ivan Walton, Ruth Poulter, Shuping Ma, Marius Comsa, Lisa Burch, Astrid Fletcher, Christopher Bulpitt. (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet Neurology 7:8, 683-689
CrossRef341
José R. González-Juanatey, Pilar Mazón Ramos. (2008) Prevención primaria farmacológica en hipertensión arterial y dislipemias. Revista Española de Cardiología 61:8, 861-879
CrossRef342
Giuseppe Mancia, Guido Grassi. (2008) Treating very elderly hypertensive patients is rewarding: The HYVET results. Current Hypertension Reports 10:4, 301-302
CrossRef343
John Webster. (2008) Size matters?. Journal of Hypertension 26:8, 1548-1550
CrossRef344
Ingmar Skoog. (2008) Antihypertensive treatment and dementia prevention. The Lancet Neurology 7:8, 664-665
CrossRef345
Debbie L. Cohen, Raymond R. Townsend. (2008) How Old Is “Too Old” to Start Treating High Blood Pressure?. The Journal of Clinical Hypertension 10:8, 647-648
CrossRef346
Javier Segovia, Javier Bermejo, Fernando Alfonso. (2008) Resumen de los ensayos clínicos presentados en la 57.a Sesión Científica Anual del American College of Cardiology (Chicago, Estados Unidos, 30 de marzo-2 de abril de 2008). Revista Española de Cardiología 61:7, 726-737
CrossRef347
Jurgen AHR Claassen. (2008) Cerebral perfusion in neurogenic orthostatic hypotension. The Lancet Neurology 7:7, 573-574
CrossRef348
Joanne M Ferguson, Jack Minas, Siky Siapantas, Paul A Komesaroff, Krishnankutty Sudhir. (2008) Effects of a Fixed-dose ACE Inhibitor-Diuretic Combination on Ambulatory Blood Pressure and Arterial Properties in Isolated Systolic Hypertension. Journal of Cardiovascular Pharmacology 51:6, 590-595
CrossRef349
Luis Miguel Ruilope, Alejandro de la Sierra. (2008) Evidencias recientes de apoyo a las guías para el tratamiento de la hipertensión arterial. Medicina Clínica 131:3, 101-103
CrossRef350
Alejandro de la Sierra, Manuel Gorostidi, Rafael Marín, Josep Redón, José R. Banegas, Pedro Armario, Juan García Puig, Julio Zarco, José L. Llisterri, Carlos Sanchís, Benjamín Abarca, Vicente Palomo, Ramón Gomis, Alfonso Otero, Fernando Villar, Jesús Honorato, Juan Tamargo, José M. Lobos, Juan Macías-Núñez, Antonio Sarría, Pedro Aranda, Luis M. Ruilope. (2008) Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. Medicina Clínica 131:3, 104-116
CrossRef351
Kostis, John B., . (2008) Treating Hypertension in the Very Old. New England Journal of Medicine 358:18, 1958-1960
Full Text352
Kohsuke MINAMISAWA. (2008) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 39:5, 163-166
CrossRef353
Richard Ian Ogilvie, Sanjiv Anand, Pierre Roy, Selwyn De Souza. (2008) Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk Factors. Clinical Drug Investigation 28:11, 673-686
CrossRef354
Zhanna D Kobalava, Yulia V Kotovskaya, Valentin S Moiseev. (2008) Efficacy and Acceptability of Indapamide Sustained Release in Elderly High-Risk Hypertensive Patients. High Blood Pressure & Cardiovascular Prevention 15:4, 275-282
CrossRef355
JATOS Study Group. (2008) Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertension Research 31:12, 2115-2127
CrossRef
- Letters
